<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">European Evidence-based (S3) Guideline for the Treatment of Acne</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">A</forename><surname>Nast</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Evidence-Based Medicine</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Klinik für Dermatologie</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Dréno</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Dermatocancerolgy</orgName>
								<orgName type="institution" key="instit1">Nantes University Hospital</orgName>
								<orgName type="institution" key="instit2">Hôtel-Dieu</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Bettoli</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Section of Dermatology</orgName>
								<orgName type="institution">University of Ferrara</orgName>
								<address>
									<settlement>Ferrara</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Z</forename><surname>Bukvic Mokos</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">University Hospital Center Zagreb</orgName>
								<address>
									<settlement>Zagreb</settlement>
									<country key="HR">Croatia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Degitz</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Dermatologist in Private Practice</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Dressler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Evidence-Based Medicine</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Klinik für Dermatologie</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Dermatology and Wound Healing</orgName>
								<orgName type="institution">Cardiff University School of Medicine</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Haedersdal</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">Bispebjerg Hospital</orgName>
								<orgName type="institution" key="instit2">University of Copenhagen</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Lambert</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">University Hospital of Antwerp</orgName>
								<orgName type="institution" key="instit2">University of Antwerp</orgName>
								<address>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Layton</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Dermatology, Harrogate and District Foundation Trust</orgName>
								<orgName type="institution">Aarhus Universitet</orgName>
								<address>
									<settlement>Harrogate, Aarhus</settlement>
									<region>North Yorkshire</region>
									<country>UK, Denmark</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Dermatology Department</orgName>
								<orgName type="institution">Alcorcon University Hospital Foundation</orgName>
								<address>
									<settlement>Alcorcón, Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Dermatology and Venereology</orgName>
								<orgName type="institution">University of Frankfurt</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Division of Dermatology and Venereology</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="institution">Karolinska University Hospital</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Private practice</orgName>
								<address>
									<settlement>Anderlecht</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Dermatology and Venereology</orgName>
								<orgName type="institution">University of Magdeburg</orgName>
								<address>
									<settlement>Magdeburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Lomholt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>López-Estebaranz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Ochsendorf</surname></persName>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Oprica</surname></persName>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Rosumeck</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Evidence-Based Medicine</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Klinik für Dermatologie</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Simonart</surname></persName>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Werner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Evidence-Based Medicine</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Klinik für Dermatologie</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
						</author>
						<author>
							<persName><forename type="first">German</forename><forename type="middle">(</forename><surname>Germany</surname></persName>
						</author>
						<title level="a" type="main">European Evidence-based (S3) Guideline for the Treatment of Acne</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">8477359E4303EEEB3EFA0FD9DA3640EB</idno>
					<note type="submission">Formatted: Highlight Deleted: Table 10 Formatted: Highlight Deleted: Table 11 Formatted: Highlight Deleted: Table 4 Formatted: Highlight Deleted: Table 11</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:30+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>French (France)</keywords>
			</textClass>
			<abstract xml:lang="it">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>LE=level of evidence; ne=no evidence; top.=topical</s><s>* BPO 5% = tretinoin 0.1% (LE 4); tretinoin 0.025% &gt; BPO 5% (LE 4) ** adapalene 0.1% = tretinoin 0.025% (LE 1); tretinoin 0.05% ≥ adapalene 0.1% (LE 4); TMG 0.1% ≥ adapalene 0.1% (LE 4)</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1">Notes on use of guideline</head><p><s>An evidence-based guideline has been defined as 'a systematically developed statement that assists clinicians and patients in making decisions about appropriate treatment for a specific condition' <ref type="bibr" target="#b0">[1]</ref>.</s><s>A guideline will never encompass therapy specifications for all medical decision-making situations.</s><s>Deviation from the recommendations may, therefore, be justified in specific situations.</s><s>This is not a textbook on acne, nor a complete, all-inclusive reference on all aspects important to the treatment of acne.</s><s>The presentation on safety in particular is limited to the information available in the included clinical trials and does not represent all the available and necessary information for the treatment of patients.</s><s>Additional consultation of specific sources of information on the particular intervention prescribed (e. g. product information sheet) is necessary.</s><s>Furthermore, all patients should be informed about the specific risks associated with any given topical and/ or systemic therapy.</s></p><p><s>Readers must carefully check the information in this guideline and determine whether the recommendations contained therein (e. g. regarding dose, dosing regimens, contraindications, or drug interactions) are complete, correct, and up-to-date.</s><s>The authors and publishers can take no responsibility for dosage or treatment decisions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2">Objectives of the guideline</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Improvement in the care of acne patients</head><p><s>The idea behind this guideline is that recommendations based on a systematic review of the literature and a structured consensus process will improve the quality of acne therapy in general.</s><s>Personal experiences and traditional therapy concepts should be critically evaluated and replaced, if applicable, with the consented therapeutic recommendations.</s><s>In particular, a correct choice of therapy should be facilitated by presenting the suitable therapy options in a therapy algorithm, taking into account the type of acne and the severity of the disease.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduction of serious conditions and scarring</head><p><s>As a result of the detailed description of systemic therapies for patients with severe acne, reservations about these interventions should be overcome to ensure that patients receive the optimal therapy.</s><s>With the timely introduction of sufficient therapies, the development of serious post-acne conditions, severe scarring and adverse psychosocial impact should be reduced.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Promotion of adherence</head><p><s>Good therapeutic adherence is key to treatment success.</s><s>Adherence is facilitated by knowledge of the product being used, for example treatment duration, the expected onset of effect, the sequence of the healing process, the maximal achievable average effect, expected adverse events, and the benefit to quality of life.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduction of antibiotic resistance</head><p><s>The use of topical and systemic antibiotics should be optimized by using appropriate combinations for a predefined duration, in order to reduce the development of antibiotic resistance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3">Target population</head><p><s>Health care professionals This guideline has been developed to help health care professionals provide optimal therapy to patients with mild, moderate or severe acne.</s><s>The primary target groups are dermatologists and other professionals involved in the treatment of acne, such as paediatricians and general practitioners.</s><s>The target group may vary with respect to national differences in the distribution of services provided by specialists or general practitioners.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>The recommendations of the guideline refer to patients who suffer from acne.</s><s>These are mainly adolescents treated in outpatient clinics.</s><s>The appropriate therapy option is presented according to the type of acne that is present.</s><s>The primary focus is the induction therapy of facial acne, recommendations also encompass patients with more widespread acne affecting the trunk (see Chapter 1.6).</s><s>Non-primary target groups are patients with special forms of acne, such as, occupational acne, chloracne, acne aestivalis, acne neonatorum and acne inverse (hidradenitis suppurativa).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.4">Pharmacoeconomic considerations</head><p><s>European guidelines are intended for adaptation to national conditions.</s><s>It is beyond the scope of this guideline to take into consideration the specific costs and reimbursement situations in every European country.</s><s>Differences in prices, reimbursement systems, willingness and ability to pay for medication among patients and the availability of generics are too large.</s><s>Therefore, pharmacoeconomic considerations will have to be taken into account when guidelines are developed at national and local levels.</s></p><p><s>The personal financial and health insurance situation of a patient may necessitate amendments to the prioritisation of treatment recommendations.</s><s>However, if financial resources allow, the suggested ranking in the therapeutic algorithm should be pursued.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.5">Considerations with respect to vehicle for topical treatments</head><p><s>The skin type, the sex and stage of disease has to be taken into consideration when choosing the vehicle for topical treatments.</s><s>The efficacy and safety/ tolerability of topical treatments are influenced by the choice of vehicle.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.6">Considerations regarding area of involvement</head><p><s>The face is the primary region of interest for the treatment of acne.</s><s>Appearance, scarring, quality of life and social stigmatization are important considerations when dealing with facial dermatological diseases.</s></p><p><s>The recommendations of this guideline apply primarily to the treatment of facial acne.</s><s>More widespread involvement will certainly favour earlier use of a systemic treatment due to the efficacy and practicability of such treatments.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.7">Clinical features and variants</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Layton/ Finlay</head><p><s>Acne (synonym "acne vulgaris") is a polymorphic, inflammatory skin disease nearly always affecting the face (99 % of cases).</s><s>It also commonly affects the back (60 %) and chest (15 %) <ref type="bibr" target="#b1">[2]</ref>.</s><s>Seborrhoea is a frequent feature <ref type="bibr" target="#b2">[3]</ref>.</s></p><p><s>The clinical picture embraces a spectrum of signs, ranging from mild comedonal acne, with or without sparse inflammatory lesions (IL), to acne conglobate or aggressive fulminate disease with deep-seated inflammation, nodules and in some cases associated systemic symptoms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.7.1">Comedonal acne</head><p><s>Clinically non-inflamed lesions develop from the subclinical microcomedo which is evident on histological examination early in acne development <ref type="bibr" target="#b1">[2]</ref>.</s><s>Non-inflamed lesions encompass both open (blackheads) and closed comedones (whiteheads).</s></p><p><s>Comedones frequently have a mid-facial distribution in childhood and, when evident early in the course of the disease, this pattern is indicative of poor prognosis <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>Closed comedones are often inconspicuous with no visible follicular opening.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.7.2">Papulopustular acne</head><p><s>Most patients have a mixture of non-inflammatory (NIL) and inflammatory lesions <ref type="bibr" target="#b4">[5]</ref>.</s><s>Inflammatory lesions arise from the microcomedo or from non-inflammatory clinically apparent lesions and may be either superficial or deep <ref type="bibr" target="#b5">[6]</ref>.</s><s>Superficial inflammatory lesions include papules and pustules (5 mm or less in diameter).</s><s>These may evolve into nodules in more severe disease.</s><s>Inflammatory macules represent regressing lesions that may persist for many weeks and contribute markedly to the general inflammatory appearance <ref type="bibr" target="#b4">[5]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.7.3">Nodular/ conglobate acne</head><p><s>Nodules are defined as firm, inflamed lesions &gt;10 mm diameter, painful by palpation.</s><s><ref type="bibr" target="#b6">[7]</ref>.</s><s>They may extend deeply and over large areas, frequently resulting in painful lesions, exudative sinus tracts and tissue destruction.</s><s>Conglobate acne is a rare but severe form of acne found most commonly in adult males with few or no systemic symptoms.</s><s>Lesions usually occur on the trunk and upper limbs and frequently extend to the buttocks.</s><s>In contrast to ordinary acne, facial lesions are less common.</s><s>The condition often presents in the second to third decade of life and may persist into the Deleted: with respect to body area sixth decade.</s><s>Conglobate acne is characterized by multiple grouped comedones amidst inflammatory papules, tender, suppurative nodules which commonly coalesce to form sinus tracts.</s><s>Extensive and disfiguring scarring is frequently a feature.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.7.4">Other acne variants</head><p><s>There are several severe and unusual variants or complications of acne as well as other similar diseases.</s><s>These include acne fulminans, gram-negative folliculitis, rosacea fulminans, vasculitis, mechanical acne, oil/ tar acne, chloracne, acne in neonates and infants and late onset, persistent acne, sometimes associated with genetic or iatrogenic endocrinopathies.</s><s>The current guideline do not lend themselves to comprehensive management of all of these variants.</s></p><p><s>2 Assessment, comparability of treatment outcomes Finlay/ Layton</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Acne grading</head><p><s>Acne can be largely assessed from two perspectives: objective disease activity (based on measurement of visible signs) and quality of life impact.</s><s>There are other aspects of measurement, such as sebum excretion rate, colonisation by Propionibacterium acnes (P.</s><s>acnes), scarring development or economic impact.</s></p><p><s>Accurately assessing outcomes from therapy is notoriously difficult in acne <ref type="bibr" target="#b7">[8]</ref>.</s><s>Many different approaches have been adopted but very few are validated.</s><s>The inconsistent application of a standard method for assessing acne severity makes it very difficult to challenge interpretation of results from interventional studies.</s><s>There are detailed reviews and reflections on this subject by Lehmann et al. <ref type="bibr" target="#b8">[9]</ref>, Barratt et al. <ref type="bibr" target="#b9">[10]</ref>, Witkowski et al. <ref type="bibr" target="#b10">[11]</ref>, Thiboutot et al. <ref type="bibr" target="#b11">[12]</ref>, Gollnick et al. <ref type="bibr" target="#b12">[13]</ref> and Tan et al. <ref type="bibr" target="#b13">[14]</ref>.</s></p><p><s>Proper lighting, appropriate patient positioning and prior facial skin preparation (gentle shaving for men, removal of make-up for women) are helpful in facilitating accurate assessment.</s><s>Palpation in addition to visual inspection may also help define lesions more accurately.</s></p><p><s>Mechanisms to assess acne lesions using digital multimodal imaging are being evaluated but have not yet been accepted or validated for use in clinical practice <ref type="bibr" target="#b14">[15]</ref>.</s><s>Patient reported outcomes are now also being considered as an important part of overall assessment <ref type="bibr" target="#b15">[16]</ref>.</s><s>However, the most frequently used outcome measures to assess acne involve grading or counting.</s><s>These evaluations can be further divided into: (i) an evaluation according to the predominant lesion type; (ii) evaluations of separate individual lesions; (iii) overall or 'global' assessment.</s><s>Lesion counts are essential for clinical trials as they offer a reliability not evident in global assessment, however counting remains impractical for use in the day-to-day clinic <ref type="bibr" target="#b16">[17]</ref> and does not accurately reflect overall severity <ref type="bibr" target="#b17">[18]</ref>.</s><s>In systematic reviews, global grading has been used as an efficacy measure in up to 62% of acne trials <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref> and the USA Food and Drug Administration (FDA) has mandated global grading as one of two efficacy measures in which superiority must be demonstrated for approval of acne therapies <ref type="bibr" target="#b17">[18]</ref>.</s><s>However, no one global system has been established as a standard: some utilize quantitative measures e. g. lesion counts and numeric ranges and others are based on qualitative descriptions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.1">Acne grading systems</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.1.1">Sign-based methods</head><p><s>Despite a range of methods being used to measure acne in the 1960's and 1970's, it was the Leeds technique <ref type="bibr" target="#b4">[5]</ref> that dominated acne measurement for the next two decades.</s><s>The Leeds technique included two methods; the grading technique and the counting technique.</s><s>The grading technique allocated patients a grade from 0 to 10, with seven subgroups between 0 and 2. Photographic guides illustrating each grade are given, but the importance of also palpating lesions is stressed.</s><s>The experience on which this system was based stemmed from the pre-isotretinoin era, and acne of the severity described by grades above 2 is now rarely seen.</s><s>The counting technique involves the direct counting of non-inflamed and inflamed lesions, including superficial papules and pustules, deep inflamed lesions and macules.</s><s>The revised Leeds acne grading system <ref type="bibr" target="#b18">[19]</ref> includes numerical grading systems for the back and chest as well as for the face.</s></p><p><s>The Echelle de Cotation des Lesions d'Acne (ECLA) or "Acne Lesion Score Scale" system has demonstrated good reliability <ref type="bibr" target="#b19">[20]</ref>.</s><s>However, ECLA scores do not correlate with quality of life scores and the use of both disease and quality of life scores is suggested <ref type="bibr" target="#b21">[21]</ref>.</s></p><p><s>Persisting hyperpigmentation after active acne has settled is of great concern to many patients.</s><s>An instrument to measure this has been described, the post acne hyperpigmentation index (PAHPI) <ref type="bibr" target="#b23">[22]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.1.2">Global assessment techniques</head><p><s>Global assessment scales incorporate the entirety of the clinical presentation into a single category of severity.</s><s>Each category is defined by either photographs with a corresponding numeric scale or by descriptive text.</s><s>Grading is a subjective task, based on observing dominant lesions, evaluating the presence or absence of inflammation, which is particularly difficult to capture, and estimating the extent of involvement.</s><s>Global methods are much more practically suited to clinical practice.</s><s>In clinical investigations, they should be combined with lesion counts as a co-primary endpoint of efficacy <ref type="bibr" target="#b24">[23]</ref>.</s><s>A simple photographic standard-based grading method using a 0-8 scale has been successfully employed in several clinical trials <ref type="bibr" target="#b25">[24]</ref>.</s></p><p><s>A very simple classification of acne severity was described in the 2003 report from the Global Alliance for better outcome of acne treatment <ref type="bibr" target="#b12">[13]</ref>.</s><s>This basic classification was designed to be used in a routine clinic, and its purpose was to map treatment advice onto common clinical presentations.</s><s>For each acne descriptor a first-choice therapy is advised, with alternatives for females and maintenance therapy.</s><s>There are five simple descriptors: mild comedonal, mild papulopustular, moderate papulopustular, moderate nodular, and severe nodular/ conglobate.</s><s>A series of eight photographs span and overlap these five descriptors.</s><s>Different facial views and different magnifications are used, reducing the comparability of the images.</s></p><p><s>In 2005, the FDA proposed an investigator global assessment (IGA) that represented a static quantitative evaluation of overall acne severity.</s><s>To accomplish this, they devised an ordinal scale with five severity grades, each defined by distinct and clinically relevant morphological descriptions that they hoped would minimise interobserver variability.</s><s>Indeed, the more detailed descriptive text has resulted in this system being considered to provide even greater reliability than previous global assessments <ref type="bibr" target="#b17">[18]</ref>.</s></p><p><s>The Comprehensive Acne Severity System (CASS), was developed by extending a pre-existing 6-category facial IGA scale, ranging from clear through to very severe grading, to include the chest and back <ref type="bibr" target="#b26">[25]</ref>.</s><s>This has been validated and provides a global system that includes a restricted number of categories to allow for a practical and comprehensive approach when assessing treatment outcomes.</s></p><p><s>In order to give treatment recommendations based on disease activity, the EU Guideline group has considered how best to classify acne patients.</s><s>It has used the following simple clinical classification: However, in many cases the systems do not include corresponding categories and often it has to be considered an approximated attempt rather than a precise mapping (Table <ref type="table" target="#tab_2">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.1.3">Quality of life methods</head><p><s>The use of Quality of Life (QoL) measures captures the impact of acne as well as the impact of treatment on the patient's life and as a result supports identification of those vulnerable to psychological complications.</s><s>Adopting a QoL measure as an integral part of acne management is recommended.</s><s>In order for quality of life measures to be used more frequently in routine clinical work, they need to be easy to use, the scores need to be meaningful, and they need to be readily accessible.</s><s>It is possible to measure the impact of acne on quality of life using several questionnaires.</s><s>There are acne-specific, dermatology-specific and generic measures, which can be used across all diseases.</s></p><p><s>Acne specific measures include the "Assessments of the Psychological and Social Effects of Acne" (APSEA) questionnaire <ref type="bibr" target="#b36">[35,</ref><ref type="bibr" target="#b37">36]</ref>, the Cardiff Acne Disability Index <ref type="bibr" target="#b38">[37,</ref><ref type="bibr" target="#b39">38]</ref> the Acne Quality of Life Scale (AQOL) <ref type="bibr" target="#b40">[39]</ref>, the Acne-specific Quality of Life Questionnaire (Acne-QoL) <ref type="bibr" target="#b41">[40]</ref> and the short version of this, the Acne-Q4 <ref type="bibr" target="#b42">[41]</ref>.</s><s>A recent novel patient reported outcome measure, the Acne Symptom and Impact Scale (ASIS) seeks to capture both symptoms and impacts of facial acne <ref type="bibr" target="#b43">[42,</ref><ref type="bibr" target="#b44">43]</ref>.</s></p><p><s>Dermatology specific measures used in acne include the Dermatology Life Quality Index (DLQI) <ref type="bibr" target="#b45">[44]</ref><ref type="bibr" target="#b46">[45]</ref><ref type="bibr" target="#b47">[46]</ref>, the Children's Dermatology Life Quality Index (CDLQI) <ref type="bibr" target="#b48">[47]</ref> and Skindex-29, -16 <ref type="bibr" target="#b49">[48]</ref>.</s><s>Generic measures used in acne include the SF-36 <ref type="bibr">(Mallon)</ref> and the General Health Questionnaire <ref type="bibr" target="#b50">[49]</ref>.</s></p><p><s>In addition it is possible to measure the secondary impact of acne on the lives of partners and other family members, using a dermatology specific measure, the Family Dermatology Life Quality Index <ref type="bibr" target="#b51">[50]</ref> and a generic measure, the Family Reported Outcome Measure (FROM-16) <ref type="bibr" target="#b52">[51]</ref>.</s></p><p><s>Acne also affects functional abilities.</s><s>Patients are prone to embarrassment and social withdrawal, depression, anxiety and anger.</s><s>The combined use of QoL and psychosocial questionnaires is essential to adequately understand just how severely</s></p><formula xml:id="formula_0">Formatted: English (United Kingdom)</formula><p><s>the disease is affecting a patient, and can aid in assessing the efficacy of therapy and justifying clinical decisions.</s><s>In patients with a severe impact on their quality of life, a more aggressive therapy may be justified.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Prognostic factors that should influence treatment choice 2.2.1 Prognostic factors of disease severity</head><p><s>A number of prognostic factors relating to more severe disease should be considered when assessing and managing acne.</s><s>These are outlined and evidenced in review papers published by Holland and Jeremy 2005 <ref type="bibr" target="#b53">[52]</ref> and <ref type="bibr">Dreno et al. 2006 [53]</ref> and include family history, course of inflammation, persistent or late-onset disease, hyperseborrhoea, androgenic triggers, truncal acne and/ or psychological sequelae.</s><s>Previous infantile acne may also correlate with resurgence of acne at puberty and early age of onset with mid-facial comedones, early and more severe seborrhoea and earlier presentation relative to the menarche are all factors that should alert the clinician to increased likelihood of more severe acne.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.2">The influence of the assessment of scarring/ potential for scarring on disease management</head><p><s>Scarring usually follows deep-seated inflammatory lesions, but may also occur as a result of more superficial inflamed lesions in scar-prone patients.</s><s>Acne scarring, albeit mild, has been identified in up to 95 % of patients attending a dermatology clinic <ref type="bibr" target="#b55">[54]</ref>.</s><s>Scars may show increased collagen (hypertrophic and keloid scars) or be associated with collagen loss which is a more frequent consequence of inflammatory acne <ref type="bibr" target="#b56">[55]</ref>.</s><s>The duration of inflammation relates to scar production hence a delay in appropriate management is more likely to result in significant scarring <ref type="bibr" target="#b26">[25,</ref><ref type="bibr" target="#b55">54]</ref>.</s></p><p><s>Acne scarring should also be included in the assessment of acne severity.</s><s>Scars can produce significant disfigurement and psychosocial impairment in their own right.</s><s>The difficulty in evaluation of acne scars is manifold and clinical assessment of scars demonstrates significant variation between assessors <ref type="bibr" target="#b57">[56]</ref>.</s><s>Several different systems have been described to evaluate acne scars (see Table <ref type="table" target="#tab_3">2</ref>).</s><s>Other techniques have been employed in an attempt to quantify scarring at specified time points in relation to treatment.</s><s>These include ultrasound <ref type="bibr" target="#b58">[57]</ref> surface profilometry using silicone imprints <ref type="bibr" target="#b59">[58]</ref>, standardized photography <ref type="bibr" target="#b60">[59]</ref>, and three dimensional in vivo microtopography measurements <ref type="bibr" target="#b61">[60]</ref>.</s></p><p><s>However, to date no single validated method to evaluate the extent or volume deficiency of acne scars has been uniformly adopted for use in routine clinical practice.</s></p><p><s>The presence of scarring should support aggressive management and therapy should be commenced early in the disease process.</s></p><p><s>Acne Scar System Severity Scheme Regional Relevance Leeds <ref type="bibr" target="#b55">[54]</ref> Numeric (Maximum  <ref type="bibr" target="#b71">[70]</ref> and usually subsides after the end of growth.</s><s>However, to some degree, acne may persist beyond teen age in a significant proportion of individuals <ref type="bibr" target="#b72">[71]</ref>.</s><s>Even after the disease has ended, acne scars and hyper-or hypopigmentation are not uncommon permanent negative outcomes <ref type="bibr" target="#b11">[12]</ref>.</s><s>Genetic factors have been recognized <ref type="bibr" target="#b73">[72]</ref>.</s><s>There is a high concordance among identical twins, and there is also a tendency towards severe acne in patients with a positive family history <ref type="bibr" target="#b74">[73]</ref>.</s></p><p><s>Multiple genes are probably involved in acne predisposition, among others cytochrome P450-1A1 and several enzymes involved in androgen metabolism <ref type="bibr" target="#b75">[74,</ref><ref type="bibr" target="#b76">75]</ref>.</s><s>A genome-wide association study revealed a role for the dysregulation of TGFβmediated signalling in the susceptibility to acne <ref type="bibr" target="#b77">[76]</ref>.</s><s>Environmental factors also appear to be of relevance for acne prevalence.</s><s>Of note, diet has recently gained attention.</s><s>Populations with a natural lifestyle do not develop acne <ref type="bibr" target="#b78">[77]</ref>, and epidemiologic <ref type="bibr" target="#b79">[78]</ref> and investigative studies <ref type="bibr" target="#b80">[79]</ref> correlate acne with Western diet.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Pathophysiology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dréno/ Gollnick</head><p><s>Acne is an androgen-dependent disorder of pilosebaceous follicles (or pilosebaceous unit).</s><s>There are four primary pathogenic factors, which interact to produce acne lesions: 1) sebum production by the sebaceous gland, 2) alteration in the follicular keratinization process, 3) Propionibacterium acnes follicular colonization, and 4) release of inflammatory mediators.</s></p><p><s>Patients with seborrhoea and acne have a significantly greater number of lobules per gland compared with unaffected individuals (the so-called genetically prone "Anlage").</s><s>Inflammatory responses occur prior to the hyperproliferation of keratinocytes.</s><s>Interleukin-1α up-regulation contributes to the development of comedones independent of the colonization with P. acnes.</s><s>A relative linoleic acid deficiency has also been described.</s></p><p><s>Sebaceous lipids are regulated by peroxisome proliferator-activated receptors which act in concert with retinoid X receptors to regulate epidermal growth and differentiation as well as lipid metabolism.</s><s>Sterol response element binding proteins mediate the increase in sebaceous lipid formation induced by insulin-like growth factor-1.</s><s>Substance P receptors, neuropeptidases, α-melanocyte stimulating hormone, insulin-like growth factor (IGF)-1R and corticotrophin-releasing hormone (CRH)-R1 are also involved in regulating sebocyte activity as are the ectopeptidases, such as dipeptidylpeptidase IV and animopeptidase N. The sebaceous gland also acts as an endocrine organ in response to changes in androgens and other hormones.</s><s>DHEA-S is a stimulator of IL-2 driven T-cells and, therefore, driving the inflammatory process.</s><s><ref type="bibr" target="#b81">[80]</ref> Oxidized squalene can stimulate hyperproliferative behaviour of keratinocytes, and lipoperoxides produce leukotriene B4, a powerful chemoattractant.</s></p><p><s>Microcomedones, macules and further developed visible lesions of acne produces chemotactic factors and promote the synthesis of tumour necrosis factor- and interleukin-1.</s><s>Another cytokine, IL-17 has been identified as potentially playing an important role in addition of IL-1β in acne <ref type="bibr" target="#b82">[81]</ref>.</s><s>Cytokine induction by P. acnes occurs through Toll-like receptor (TLR) 2 activation via activation of nuclear factor-B and activator protein 1 (AP-1) transcription factor.</s><s>P acnes activates also Protease activated Receptor (PAR) 2. <ref type="bibr" target="#b83">[82]</ref> Both TLR and PAR belongs to the innate immunity and play a crucial role in the modulation and duration of inflammation of acne lesions in association with the antimicrobial peptides.</s><s><ref type="bibr" target="#b84">[83]</ref> Activation of AP-1 induces matrix metalloproteinase genes, the products of which degrade and alter the dermal matrix and could be a central factor in the development of acne scars.</s><s>Recent data indicate that the phylotypes of P acnes are different comparing healthy controls and acne patients and in addition that different phylotypes of P acnes have different pro inflammatory activities, modulating differently the innate immunity.</s><s><ref type="bibr" target="#b85">[84]</ref><ref type="bibr" target="#b86">[85]</ref><ref type="bibr" target="#b87">[86]</ref><ref type="bibr" target="#b88">[87]</ref> P acnes as the therapeutic target has become questionable after studies showing that not all follicles are P acnes colonized, the number of P acnes are not correlating with the intensity of inflammatory reactions and course of the disease, but certain strains are correlating with the severity grade and course of acne.</s><s><ref type="bibr" target="#b89">[88]</ref> Recently, it could be shown that the inflammasome is activated and IL-1ß is activated <ref type="bibr" target="#b90">[89]</ref>.</s><s>Furthermore, new findings on the role of growth factors such as IGF-1 in the regulation of the sebocytes have demonstrated that transcriptional factors such as FOX-O1 can interact with PPAR gamma and sebocyte differentiation and proliferation and may give some hint to a possible role of diets in the daily practice of acne patients.</s><s>However, it could be shown for the first time that those growth factors also upregulate TLR 2 and 4.</s><s>This means that not only P acnes is a key for upregulating TLR <ref type="bibr" target="#b91">[90]</ref>.</s></p><p><s>The improved understanding of acne development on a molecular level suggests that acne is a disease that involves both innate and adaptive immune systems with a predominant role for innate immunity in the regulation of inflammatory events.</s></p><p><s>4 Methods -Assessment of evidence (For further details please see the methods report at www.acne-guideline.com.)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nast/ Rosumeck</head><p><s>Many different grading systems for assessing the quality of evidence are available in the field of guideline development.</s><s>For this guideline, the authors used the grading system adopted from the European Psoriasis Guideline (version 2010) <ref type="bibr" target="#b92">[91,</ref><ref type="bibr" target="#b93">92]</ref>, already used in the previous acne guideline 2011 <ref type="bibr" target="#b94">[93,</ref><ref type="bibr" target="#b95">94]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Grade of evidence (quality of individual trial)</head><p><s>The available literature was evaluated with respect to the methodological quality of each single trial.</s><s>A grade of evidence was given to every individual trial included:</s></p><formula xml:id="formula_1">A Randomized,</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">Level of evidence (quality of body of evidence to answer a specific question)</head><p><s>When looking at a specific question (e. g. efficacy of BPO relative to adapalene) the available evidence was summarized by aligning a level of evidence (LE), as our criteria were combined with the definition of GRADE <ref type="bibr" target="#b96">[95]</ref> as used in the 2011 acne guideline version:</s></p><p><s>1</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Further research is very unlikely to change our confidence in the estimate of effect.</head><p><s>At least two trials are available that were assigned a grade of evidence A and the results are predominantly consistent with the results of additional grade B or C studies.</s></p><p><s>2</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</head><p><s>At least three trials are available that were assigned a grade of evidence B and the results are predominantly consistent with respect to additional grade C trials.</s></p><p><s>3</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</head><p><s>Conflicting evidence or limited amount of trials, mostly with a grade of evidence of B or C.</s></p><p><s>4</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Any estimate of effect is very uncertain.</head><p><s>Little or no systematic empirical evidence; included trials are extremely limited in number and/ or quality.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3">Consensus process</head><p><s>All recommendations were agreed on in an online-telephone consensus conference using a formal and structured consensus methodology.</s><s>The consensus conference was moderated by PD Dr. med.</s><s>Alexander Nast, who is a certified moderator for the German Association of Scientific Medical Societies (AWMF).</s><s>All nominated experts were entitled to vote in the consensus conference.</s></p><p><s>In order to weight the different recommendations, the group assigned a "strength of recommendation" grade (see box below).</s><s>The strength of recommendation considered all aspects of the treatment decision, such as efficacy, safety, patient preference, and the reliability of the existing body of evidence (level of evidence).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strength of recommendation</head><p><s>In order to grade the recommendation a "standardized guideline" language was used:</s></p><p><s>1) is strongly recommended 2) can be recommended 3) can be considered 4) is not recommended 5) may not be used under any circumstances 6) a recommendation for or against treatment X cannot be made at the present time.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">Induction therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of therapeutic recommendations 1 for induction therapy</head><p><s>Recommendations are based on available evidence and expert consensus.</s><s>Available evidence and expert voting lead to classification of strength of recommendation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comedonal acne 3</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mild to moderate papulopustular acne</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Severe papulopustular/ moderate nodular acne</head><p><s>Severe nodular/ conglobate acne 12   High strength of recommendation -Adapalene + BPO (f.c.) or BPO + Clindamycin (f.c.) 5   Isotretinoin Isotretinoin</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Medium strength of recommendation</head><p><s>Topical retinoid 4   Azelaic acid or BPO or Topical Retinoid 4  or Topical Clindamycin + Tretinoin (f.c.) 5  or Systemic Antibiotic 5,6,7  + Adapalene 8 Systemic Antibiotic 5,7 + Adapalene 8 or Systemic Antibiotic 5,7  + Azelaic acid 9 or Systemic Antibiotic 5,7  + Adapalene + BPO (f.c.) Systemic Antibiotic 5,7 + Azelaic Acid or Systemic Antibiotic 5,7 + Adapalene + BPO (f.c.)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Low strength of recommendation</head><p><s>Azelaic acid or BPO Blue Light or Oral Zinc or Systemic Antibiotic 5,6,7  + Azelaic Acid 9 or Systemic Antibiotic 5,6,7  + Adapalene + BPO (f.c.) 10  or Systemic Antibiotic 5,6,7  + BPO 11  or Topical Erythromycin + Isotretinoin (f.c.) 5  or Topical Erythromycin + Tretinoin (f.c.) 5   Systemic Antibiotic 5,7 + BPO 11   Systemic Antibiotic Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation as a first line therapy (e. g. financial resources/ reimbursement limitations, legal restrictions, availability, drug licensing).</s><s>In case of more widespread disease/ moderate severity, initiation of a systemic treatment can be recommended.</s><s>indirect evidence from a study also including chlorhexidin, recommendation additionally based on expert opinion 12 systemic treatment with corticosteroids can be considered 13 the f.c. of clindamycin/tretinoin shows comparable efficacy and safety to the f.c.</s><s>BPO/clindamycin, downgrading to a medium strength of recommendation was done based on concerns with respect to the development of antibiotic resistance f.c.</s><s>fixed combination</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1">Treatment of comedonal acne</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1.1">Recommendations for comedonal acne</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>High strength of recommendation None</head><p><s>Medium strength of recommendation Topical retinoids 2 can be recommended for the treatment of comedonal acne.</s></p><p><s>Low strength of recommendation Azelaic acid can be considered for the treatment of comedonal acne.</s><s>BPO can be considered for the treatment of comedonal acne.</s></p><p><s>Open recommendation A recommendation for or against treatment of comedonal acne with visible light as monotherapy, lasers with visible wavelengths and lasers with infrared wavelengths, with intense pulsed light (IPL) and photodynamic therapy (PDT) cannot be made at the present time.</s></p><p><s>Negative recommendation Topical antibiotics are not recommended for the treatment of comedonal acne.</s><s>Hormonal antiandrogens, systemic antibiotics and/ or systemic isotretinoin are not recommended for the treatment of comedonal acne.</s><s>Artificial ultraviolet (UV) radiation is not recommended for the treatment of comedonal acne.</s></p><p><s>1 Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation as a first line therapy (e. g. financial resources/ reimbursement limitations, legal restrictions, availability, drug licensing).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1.2">Reasoning</head><p><s>General comment: Only one trial looks specifically at patients with comedonal acne.</s><s>As a source of indirect evidence, trials including patients with papulopustular acne were used and the percentage in the reduction of non-inflammatory lesions was considered as the relevant outcome parameter.</s><s>Because of the general lack of direct evidence for the treatment of comedonal acne, the strength of recommendation was 1 downgraded for all considered treatment options, starting with medium strength of recommendation as a maximum.</s></p><p><s>Due to the usually mild to moderate severity of comedonal acne, generally a topical therapy is recommended.</s></p><p><s>The best efficacy was shown for topical retinoids, BPO and azelaic acid.</s></p><p><s>The tolerability of topical retinoids and BPO is comparable; there is a trend towards azelaic acid having a better safety/ tolerability profile than BPO and a comparable profile to adapalene (indirect evidence, see Table <ref type="table" target="#tab_18">11</ref>).</s></p><p><s>The fixed dose combination of adapalene with BPO shows a trend towards better efficacy against non-inflammatory lesions (NIL) when compared to BPO and a comparable efficacy when compared to adapalene (see Table <ref type="table" target="#tab_8">4</ref>).</s><s>However, there is also a trend towards inferiority of the fixed combination with respect to the safety/ tolerability profile (indirect evidence, see Table <ref type="table" target="#tab_19">12</ref>).</s></p><p><s>The fixed dose combinations of clindamycin with BPO showed a trend towards better efficacy against NIL versus clindamycin and comparable efficacy versus BPO (see Table <ref type="table" target="#tab_9">5</ref>).</s><s>With respect to the safety/ tolerability profile, the combination is comparable to its single components (indirect evidence, see Table <ref type="table" target="#tab_19">12</ref>).</s></p><p><s>Few and only indirect data on patient preference are available.</s><s>They indicate patient preference for adapalene over other topical retinoids.</s></p><p><s>Additional pathophysiological considerations favour the use of topical retinoids (reduction of microcomedones).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1.2.1">Efficacy</head><p><s>See Table <ref type="table" target="#tab_7">3</ref> to Table <ref type="table" target="#tab_9">5</ref> for summary of efficacy data.</s><s>Please see methods report for explanation of assessment strategy.</s></p><formula xml:id="formula_2">BPO = i LE 3 t ≥ BPO LE 4* Azelaic acid (aa) aa &gt; v LE 1 X a &gt; aa LE 4 ne t &gt; aa LE 4 Adapalene (a) a &gt; v LE 1 X X a = i LE 4 a = t LE 1** Isotretinoin (i) i &gt; v LE 1 X X X i &gt; t LE 4 Tretinoin (t) t &gt; v LE 1 X X X X</formula><formula xml:id="formula_3">BPO- clinda- mycin (BPO-c) Clinda- mycin- tretino- in (ct) Adapale ne-BPO (a-BPO) a-BPO &gt; v LE 1 a-BPO &gt; BPO LE 3 a-BPO = a LE 3 ne ne ne ne X X ne BPO- clinda- mycin (BPO-c) BPO-c &gt; v LE 1 BPO-c = BPO LE 1 a = BPO-c LE 3 ne ne BPO- c &gt; c LE 1 ne BPO-c = a- BPO LE 4 X BPO-c = ct</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Light sources</head><p><s>Although in the literature search for the first version of this guideline, there were some studies for the treatment of NIL with laser and light sources, no clear recommendations could be drawn.</s><s>The published evidence was very scarce.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Deleted: 3</head><p><s>Deleted: 4</s></p><p><s>Deleted: &gt; ez ¶</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1.2.2">Safety/ tolerability</head><p><s>Only one trial looked specifically at comedonal acne.</s><s>It showed a superior safety/ tolerability profile for azelaic acid compared with tretinoin (LE 4) <ref type="bibr" target="#b97">[96]</ref>.</s></p><p><s>As a source of further indirect evidence, trials in patients with papulopustular acne were considered to evaluate the safety and tolerability profile of the included treatments.</s><s>For a summary of the data, see Chapter 5.2.3.2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1.2.3">Patient preference</head><p><s>Based on a systematic review by Dressler et al. <ref type="bibr" target="#b98">[97]</ref> there is only indirect evidence from trials including patients with mild to moderate papulopustular acne, see chapter 5.2.3.3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1.2.4">Other considerations</head><p><s>Animal experiments, in the rhino mouse model in particular, have shown for decades that retinoids have a strong anti-comedonal efficacy.</s><s>Clinical trials on the microcomedo, the natural precursor of comedones, have shown that retinoids significantly reduce microcomedo counts.</s><s>In addition, in vitro data provide pathophysiological support for the use of topical retinoids for comedonal acne <ref type="bibr" target="#b99">[98,</ref><ref type="bibr" target="#b100">99]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2">Treatment of papulopustular acne</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.1">Recommendations for mild to moderate papulopustular acne 1</head><p><s>High strength of recommendation The fixed-dose combination adapalene and BPO is strongly recommended for the treatment of mild to moderate papulopustular acne.</s><s>The fixed-dose combination BPO and clindamycin 2 is strongly recommended for the treatment of mild to moderate papulopustular acne.</s></p><p><s>Medium strength of recommendation Azelaic acid can be recommended for the treatment of mild to moderate papulopustular acne.</s><s>BPO can be recommended for the treatment of mild to moderate papulopustular acne.</s></p><p><s>A combination of a systemic antibiotic 2,3,4 with adapalene 5 can be recommended for the treatment of moderate papulopustular acne.</s><s>The fixed-dose combination clindamycin and tretinoin 2 can be recommended for the treatment of mild to moderate papulopustular acne. 10</s><s> Topical retinoids 6 can be recommended for the treatment of mild to moderate papulopustular acne.</s></p><p><s>Low strength of recommendation Blue light monotherapy can be considered for the treatment of mild to moderate papulopustular acne.</s><s>Oral zinc can be considered for the treatment of mild to moderate papulopustular acne.</s></p><p><s>Systemic antibiotic 2,3,4 in combination with azelaic acid 7 can be considered for the treatment of mild to moderate papulopustular acne.</s></p><p><s>A combination of a systemic antibiotic 2,3,4 with adapalene in fixed-dose combination with BPO 8 can be considered for the treatment of moderate papulopustular acne.</s></p><p><s>A combination of a systemic antibiotic 2,3,4 with BPO 9 can be considered for the treatment of moderate papulopustular acne.</s></p><p><s>The fixed-dose combination of erythromycin and isotretinoin 2 can be considered for the treatment of mild to moderate papulopustular acne.</s></p><p><s>The fixed-dose combination of erythromycin and tretinoin 2 can be considered for the treatment of mild to moderate papulopustular acne.</s></p><p><s>Open recommendation Due to a lack of sufficient evidence, a recommendation for or against treatment of mild to moderate papulopustular acne with red light, IPL, Laser or PDT cannot be made at the present time.</s></p><p><s>Negative recommendation Topical antibiotics as monotherapy are not recommended for the treatment of mild to moderate papulopustular acne.</s><s>Artificial UV radiation is not recommended for the treatment of mild to moderate papulopustular acne.</s><s>The fixed-dose combination of erythromycin and zinc is not recommended for the treatment of mild to moderate papulopustular acne.</s><s>Systemic therapy with anti-androgens, antibiotics, and/ or isotretinoin is not recommended for the treatment of mild to moderate papulopustular acne.</s></p><p><s>1</s></p><p><s>Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation as a first line therapy (e. g. financial resources/ reimbursement limit, legal restrictions, availability, drug licensing).</s></p><p><s>2</s></p><p><s>Prescribers of antibiotics should be aware of the potential risk of the development of antibiotic resistances .</s><s>indirect evidence from a study also including chlorhexidin, recommendation additionally based on expert opinion 10 the f.c. of clindamycin/tretinoin shows comparable efficacy and safety to the f.c.</s><s>BPO/clindamycin, downgrading to a medium strength of recommendation was done based on concerns with respect to the development of antibiotic resistance</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.2">Recommendations for severe papulopustular/ moderate nodular acne 1</head><p><s>High strength of recommendation Oral isotretinoin monotherapy is strongly recommended for the treatment of severe papulopustular/ moderate nodular acne acne.</s></p><p><s>Medium strength of recommendation Systemic antibiotics 2,3 in combination with adapalene 4 , with the fixed-dose combination of adapalene and BPO, or in combination with azelaic acid 5 can be recommended for the treatment of severe papulopustular/ moderate nodular acne.</s></p><p><s>Low strength of recommendation Systemic antibiotics 2,3 in combination with BPO 5 can be considered for the treatment of severe papulopustular/ moderate nodular acne.</s></p><p><s>For females: Hormonal antiandrogens in combination with systemic antibiotic 2,3 and topicals (apart from antibiotics) can be considered for the treatment of severe papulopustular/ moderate nodular acne.</s></p><p><s>For females: Hormonal antiandrogens in combination with a topical treatment can be considered for the treatment of severe papulopustular/ moderate nodular acne.</s></p><p><s>Open recommendation Due to a lack of sufficient evidence, a recommendation for or against treatment of severe papulopustular/ moderate nodular acne with red light, IPL, Laser or PDT cannot be made at the present time.</s></p><p><s>Although PDT is effective in the treatment of severe papulopustular/ moderate nodular acne, a recommendation for or against its use cannot be made at the present time due to a lack of standard treatment regimens that ensure a favourable profile of acute adverse reaction.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Negative recommendation</head><p><s>Single or combined topical monotherapy is not recommended for the treatment of severe papulopustular/ moderate nodular acne.</s></p><p><s>Oral antibiotics as monotherapy are not recommended for the treatment of severe papulopustular/ moderate nodular acne.</s><s>Oral anti-androgens as monotherapy are not recommended for the treatment of severe papulopustular/ moderate nodular acne.</s></p><p><s>Visible light as monotherapy is not recommended for the treatment of severe papulopustular/ moderate nodular acne.</s><s>Artificial UV radiation sources are not recommended as a treatment of severe papulopustular/ moderate nodular acne.</s></p><p><s>1</s></p><p><s>Limitations can apply that may necessitate the use of a treatm ent with a lower strength of recommendation as a first line therapy (e. g. financial resources/ reimbursement limit, legal restrictions, availability, drug licensing).</s></p><p><s>2</s></p><p><s>Prescribers of antibiotics should be aware of the potential risk of the development of antibiotic resistances.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.3">Reasoning</head><p><s>Monotherapy with azelaic acid, BPO or topical retinoids showed superior efficacy when compared with vehicle.</s></p><p><s>Adapalene, azelaic acid and BPO showed comparable efficacy when compared with each other.</s><s>When comparing the topical retinoids (adapalene, isotretinoin and tretinoin) directly against each other, no relevant difference with respect to efficacy was seen.</s><s>Some conflicting evidence to the comparability of the efficacy of the treatment options above arises, when looking at the other head to head comparisons indicating superiority of BPO over isotretinoin and tretinoin over azelaic acid.</s></p><p><s>With respect to the fixed combinations, BPO/ clindamycin shows superiority over both single components.</s></p><p><s>The three fixed combinations of adapalene/ BPO, clindamycin/ tretinoin as well as erythromycin/ isotretinoin show superiority to one of the components but not to both of the components when compared individually.</s></p><p><s>Head to head comparisons of the fixed combinations of adapalene/ BPO versus BPO/ clindamycin as well as head to head comparisons of clindamycin/ tretinoin versus BPO/ clindamycin show comparable efficacy.</s></p><p><s>Due to the risk of developing antibiotic resistance, topical monotherapy with antibiotics is generally not recommended.</s><s>The potential risk of developing antibiotic resistance was taken into consideration by the expert group.</s><s>It lead to a medium strength of recommendation for the fixed combination of clindamycin/ tretinoin despite comparable efficacy and safety when compared to the fix combination of BPO/clindamycin.</s><s>The differentiation between clindamycin/ tretinoin (medium strength of recommendation) and erythromycin/ isotretinoin (low strength of recommendation) was based on evidence showing the lack of development of antibiotic resistance after 16 weeks of treatment with clindamycin/ tretinoin <ref type="bibr" target="#b101">[100]</ref> as well as indirect evidence on stronger development of antibiotic resistance to erythromycin <ref type="bibr" target="#b102">[101]</ref> and expert opinion on better follicular penetration and galenic of the clindamycin/ tretinoin formulation.</s></p><p><s>Monotherapy with azelaic acid, BPO, or topical retinoids showed comparable efficacy when compared with each other.</s></p><p><s>For severe cases, systemic treatment with isotretinoin is recommended based on the very good efficacy seen in clinical practice.</s></p><p><s>The available evidence on safety and tolerability is extremely scarce and was considered insufficient to be used as a primary basis to formulate treatment recommendations.</s></p><p><s>The lack of standardized protocols, experience and clinical trial data mean there is insufficient evidence to recommend the treatment of papulopustular acne with laser and light sources other than blue light.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Choice of topical versus systemic treatment</head><p><s>There are limited data comparing topical treatments with a systemic treatment or the additional effect of a combination of a topical plus systemic versus topical treatment only.</s><s>Most of the available trials compare a topical antibiotic monotherapy with a systemic antibiotic monotherapy.</s></p><p><s>Issues of practicability between topical and systemic treatments must also be taken into consideration in cases of severe, and often widespread, disease.</s></p><p><s>The consensus within the expert group was that most cases of severe papulopustular acne or moderate nodular acne, will achieve better efficacy when a systemic antibiotic treatment in combination with a topical treatment or if systemic isotretinoin is used.</s><s>In addition, better adherence and patient satisfaction is anticipated for systemic treatments.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.3.1">Efficacy</head><p><s>See Table <ref type="table" target="#tab_11">6</ref> to Table <ref type="table" target="#tab_16">10</ref> for summary of efficacy data.</s><s>Please see methods report for explanation of assessment strategy.</s></p><formula xml:id="formula_4">(l) l &gt; v LE 3 X X X m = l LE 4 ne ne ne Minocycline (m) m &gt; v LE 1 X X X X m = t LE 2 ne m &gt; z LE 3 Tetracycline (t) t &gt; v LE 1 X X X X X ne t &gt; z LE 3 Isotretinoin (i) i &gt; v LE 4 X X X X X X ne Deleted: 7 Deleted: 8 Zinc (z) z &gt; v LE 1 X X X X X</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Combination oral contraceptives (COCs)</head><p><s>For the previous version of the guideline, due to limited evidence, it was difficult to draw conclusions on the differences in efficacy between the anti-androgens.</s><s>For the update, the data summary from the Cochrane Review by Arowojolu et al. <ref type="bibr" target="#b103">[102]</ref> was used.</s><s>It found that: "COCs reduced acne lesion counts, severity grades and selfassessed acne compared to placebo.</s><s>Differences in the comparative effectiveness of COCs containing varying progestin types and dosages, though, were less clear.</s><s>COCs that contained chlormadinone acetate or cyproterone acetate improved acne better than levonorgestrel, although this apparent advantage was based on limited data.</s><s>A COC with cyproterone acetate might result in better acne outcomes than one with desogestrel; however, the three studies comparing these COCs produced conflicting results.</s><s>Likewise, levonorgestrel showed a slight improvement over desogestrel in acne outcomes in one trial, but a second trial found the COC groups were similar."</s><s><ref type="bibr" target="#b103">[102]</ref> Light sources</s></p><p><s>Due to the still very limited evidence, the open recommendation for IPL, laser and PDT were maintained in the update.</s><s>The low strength of recommendation for a treatment with blue light was kept based on the evidence identified in the 2011 version of the guideline and confirmed by expert voting.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.3.2">Safety/ tolerability</head><p><s>See Table <ref type="table" target="#tab_18">11</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic antibiotics</head><p><s>From the included trials, no clear conclusion can be drawn as to which antibiotic treatment has the best safety/ tolerability profile.</s></p><formula xml:id="formula_5">- cline (m) X X X X m = t LE 4 ne m &gt; z LE 4 Tetracy- cline (t) X X X X X ne insufficient data Isotre- tinoin (i) X X X X X X ne</formula><p><s>LE=level of evidence; ne=no evidence; sys.=systemic</s><s>Smith and Leyden <ref type="bibr" target="#b104">[103]</ref> performed a systemic review analyzing case reports on adverse events with minocycline and doxycycline between 1966 and 2003.</s><s>As a result, they suggest that adverse events may be less likely with doxycycline than with minocycline.</s><s>More severe adverse events seem to appear during treatments with minocycline.</s><s>Doxycycline however, leads to photosensitivity, which is not seen with minocycline.</s></p><p><s>See also Chapter 5.4.2</s><s>Choice of type of systemic antibiotic.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Combination oral contraceptives</head><p><s>The included Cochrane review by Arowojolu et al. <ref type="bibr" target="#b103">[102]</ref> does not provide definite conclusions on tolerability, safety and frequency of adverse events.</s></p><p><s>For the use of oral contraceptive, relevant safety aspects such as the risk of thrombosis have to be considered.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic treatments with isotretinoin</head><p><s>From the included trials, no clear comparison of the safety/ tolerability profiles of isotretinoin with other systemic treatments can be made.</s><s>(For a discussion of isotretinoin depression, see Chapter 0)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Light sources</head><p><s>Although in the literature search for the first version of this guideline, there were some studies for the treatment of severe nodular / conglobate acne with laser and light sources, no clear recommendations could be drawn.</s><s>The published evidence was very scarce.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.3.3">Patient preference</head><p><s>The systematic review by Dressler et al. <ref type="bibr" target="#b98">[97]</ref> includes two split-face studies reporting patient preferences for adapalene over tretinoin (low risk of bias).</s></p><p><s>Two cross-over trials evaluated erythromycin versus clindamycin but only one RCT found a statistically significant difference for patient preferences for erythromycin (unclear risk of bias).</s></p><p><s>Two split-face studies reported patient preferences for clindamycin 1%/BPO 5%/2.5% over adapalene 0.1%/BPO 2.5% (descriptive data only; unclear risk of bias).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.3.4">Other considerations</head><p><s>For further discussion on the use of isotretinoin as a first-line treatment for severe papulopustular acne, see Chapter 5.4.3.</s></p><p><s>The expert group feels strongly that the effectiveness seen in clinical practice is highest with systemic isotretinoin, although this can only be partly supported by published evidence.</s><s>Strong expert voting also took perceived lower relapse rates after treatment with isotretinoin into consideration.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3">Treatment of severe nodular/ conglobate acne</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3.1">Recommendations for severe nodular/ conglobate acne 1</head><p><s>High strength of recommendation Oral isotretinoin is strongly recommended as a monotherapy for the treatment of severe nodular/ conglobate acne.</s></p><p><s>Medium strength of recommendation Systemic antibiotics 2,3 in combination with the fixed-dose combination of adapalene and BPO or in combination with azelaic acid can be recommended for the treatment of severe nodular/ conglobate acne.</s></p><p><s>Low strength of recommendation Systemic antibiotics 2,3 in combination with adapalene 4,5 or BPO 5 can be considered for the treatment of severe nodular/ conglobate acne.</s></p><p><s>For females: Hormonal antiandrogens in combination with systemic antibiotic 2,3 and topicals (apart from antibiotics) can be considered for the treatment of severe nodular/ conglobate acne.</s></p><p><s>For females: Hormonal antiandrogens in combination with a topical treatment can be considered for the treatment of severe nodular/ conglobate acne.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Open recommendation</head><p><s>Due to a lack of sufficient evidence, it is currently not possible to make a recommendation for or against treatment with IPL or laser in severe nodular/ conglobate acne.</s></p><p><s>Although PDT is effective in the treatment of severe nodular/ conglobate acne, it cannot yet be recommended due to a lack of standard treatment regimens that ensure a favourable profile of acute adverse reaction.</s></p><p><s>Negative recommendation Topical monotherapy is not recommended for the treatment of conglobate acne.</s><s>Oral antibiotics are not recommended as monotherapy for the treatment of severe nodular/ conglobate acne.</s><s>Oral anti-androgens are not recommended as monotherapy for the treatment of severe nodular/ conglobate acne.</s><s>Artificial UV radiation sources are not recommended for the treatment of severe nodular/ conglobate acne.</s></p><p><s>Visible light as monotherapy is not recommended for the treatment of severe nodular/ conglobate acne.</s></p><p><s>1</s></p><p><s>Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation as a first line therapy (e. g. financial resources/ reimbursement limit, legal restrictions, availability, drug licensing).</s></p><p><s>2</s></p><p><s>Prescribers of antibiotics should be aware of the potential risk of the development of antibiotic resistances .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3.2">Reasoning</head><p><s>General comment: Very few of the included trials (described below) looked specifically at patients with nodular or conglobate acne.</s><s>As a source of indirect evidence, studies of patients with severe papulopustular acne were used and the percentage in the reduction of nodules (NO) and cysts (CY) in these studies was used.</s><s>In case of use of such indirect evidence, the strength of recommendation was downgraded for the considered treatment options.</s></p><p><s>Systemic isotretinoin shows superior efficacy in the treatment of severe nodular/ conglobate acne compared with systemic antibiotics, in combination with a topical treatment systemic antibiotic.</s></p><p><s>The expert group considered that the greatest effectiveness in the treatment of severe nodular/ conglobate acne in clinical practice is seen with systemic isotretinoin.</s><s>This can only be partly supported by published evidence, due to the scarcity of clinical trials in conglobate acne.</s></p><p><s>In the experts' opinion, safety concerns with isotretinoin are manageable if treatment is properly initiated and monitored.</s><s>Patient benefit with respect to treatment effect, improvement in quality of life and avoidance of scarring outweigh the side effects.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3.2.1">Efficacy</head><p><s>See Table <ref type="table" target="#tab_22">15</ref> for summary of efficacy data.</s><s>Please see methods report for explanation of assessment strategy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic monotherapy versus placebo</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic isotretinoin has superior efficacy compared with placebo [104] (LE 4 * ).</head><p><s>* There is only one trial comparing systemic isotretinoin with placebo in nodular/ conglobate acne resulting only in LE 4.</s><s>However, there are multiple trials comparing different dosage without a placebo group and following expert opinion, there is no doubt about its superior efficacy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic monotherapy versus systemic monotherapy or combination</head><p><s>See Table <ref type="table" target="#tab_22">15</ref> for summary of efficacy data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Light sources</head><p><s>Due to insufficient evidence, it is not currently possible to make a recommendation for or against treatment with IPL, laser or PDT in conglobate acne.</s><s>See also 5.2.3.1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3.2.2">Safety/ tolerability</head><p><s>See also Chapter 5.2.3.2 on the tolerability/ safety of papulopustular acne treatments.</s></p><p><s>From the trials specifically investigating severe nodular/ conglobate acne, very little information is available to compare the different treatment options.</s><s>Almost all patients Deleted: Table <ref type="table" target="#tab_21">14</ref> Deleted: Table <ref type="table" target="#tab_21">14</ref> Deleted: 14 suffer from xerosis and cheilitis during treatment with isotretinoin, whereas systemic antibiotics more commonly cause gastrointestinal adverse events.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3.2.3">Patient preference</head><p><s>The systematic review by Dressler et al. <ref type="bibr" target="#b98">[97]</ref> did not identify any evidence on the treatment preferences of patients suffering from conglobate acne.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3.2.4">Other considerations</head><p><s>For comment on EMA directive see also Chapter 5.4.3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4">General considerations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.1">Choice of type of topical retinoid</head><p><s>Adapalene should be selected in preference to tretinoin and isotretinoin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.1.1">Reasoning</head><p><s>All topical retinoids show comparable efficacy against IL (see Chapter 5.2.3.1),</s><s>whereas against NIL the evidence is conflicting (see Chapter 5.1.2.1).</s></p><p><s>Among the topical retinoids, adapalene shows the best tolerability/ safety profile followed by isotretinoin and tretinoin (see Chapter 5.</s></p><p><s>Patient preference favours adapalene over tretinoin (see Chapter 5.2.3.3).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.2">Choice of type of systemic antibiotic</head><p><s>Doxycycline and lymecycline should be selected in preference to minocycline and tetracycline.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.2.1">Reasoning</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.2.2">Efficacy</head><p><s>Doxycycline, lymecycline, minocycline and tetracycline all seem to have a comparable efficacy against IL (see Chapter 05.2.3.1).</s></p><p><s>Tetracycline showed better efficacy compared to clindamycin and comparable efficacy with erythromycin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.2.3">Safety/ tolerability</head><p><s>From the included trials, no clear results can be drawn as to which antibiotic treatment has the best safety/ tolerability profile.</s></p><p><s>Smith and Leyden <ref type="bibr" target="#b104">[103]</ref> performed a systemic review analyzing case reports on adverse events with minocycline and doxycycline between 1966 and 2003.</s><s>As a result, they suggest that adverse events may be less likely with doxycycline than with minocycline.</s><s>More severe adverse events seem to appear during treatments with Formatted: English (United States)</s></p><formula xml:id="formula_7">Deleted: 5.4.3</formula><p><s>minocycline.</s><s>Doxycycline however, leads to photosensitivity, which is not seen with minocycline.</s></p><p><s>See also Chapter 5.4.2</s><s>Choice of type of systemic antibiotic.</s></p><p><s>The most frequent ADRs for doxycycline are manageable (sun protection for photosensitivity and water intake for oesophagitis), whereas the most relevant side effects of minocycline (hypersensitivity, hepatic dysfunction, lupus like syndrome) are not easily managed <ref type="bibr" target="#b106">[105]</ref>.</s></p><p><s>The phototoxicity of doxycycline is dependent on dosage and the amount of sun light <ref type="bibr" target="#b107">[106,</ref><ref type="bibr" target="#b108">107]</ref>.</s></p><p><s>There is little information on the frequency of ADRs with lymecycline.</s><s>Its phototoxicity has been reported to be lower than with doxycycline and its safety profile is comparable to that of tetracycline <ref type="bibr" target="#b106">[105,</ref><ref type="bibr" target="#b109">108]</ref>.</s></p><p><s>More severe drug reactions are experienced during treatment with minocycline compared with doxycycline, lymecycline and tetracycline.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.2.4">Patient preference/ practicability</head><p><s>Doxycycline, lymecycline and minocycline have superior practicability compared with tetracycline due to their requirement for less frequent administration.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.2.5">Other considerations</head><p><s>The use of systemic clindamycin for the treatment of acne is generally not recommended as this treatment option should be kept for severe infections.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.3">Considerations on isotretinoin and dosage</head><p><s>The evidence on the best dosage, including cumulative dosage, is rare and partly conflicting.</s><s>In most trials, higher dosages have led to better response rates whilst having less favorable safety/ tolerability profiles.</s><s>Attempts to determine the cumulative dose necessary to obtain an optimal treatment response and low relapse rate have not yet yielded sufficient evidence for a strong recommendation.</s><s>The following recommendation is based more on expert opinion, than on existing published trials.</s></p><p><s>For severe papulopustular acne/ moderate nodular acne, a dosage of systemic isotretinoin of 0.3 -0.5 mg/kg can be recommended.</s></p><p><s>For conglobate acne a dosage of systemic isotretinoin of ≥0.5 mg/kg can be recommended.</s></p><p><s>The duration of the therapy should be at least 6 months.</s></p><p><s>In case of insufficient response, the treatment period can be prolonged.</s><s>The current European Directive for prescribing oral isotretinoin differs from the recommendations given in this guideline.</s></p><p><s>The EU directive states: "oral isotretinoin should only be used in severe acne, nodular and conglobate acne, that has or is not responding to appropriate antibiotics and topical therapy" <ref type="bibr" target="#b110">[109]</ref>.</s><s>The inference of this being that isotretinoin should now not be used as first-line therapy.</s></p><p><s>After almost three decades of experience with oral isotretinoin, the published data and opinion of many experts, including the authors of the EU Acne Guideline, support systemic isotretinoin being considered as the first-choice treatment for severe papulopustular, moderate nodular, and severe nodular/ conglobate acne <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b111">[110]</ref><ref type="bibr" target="#b112">[111]</ref><ref type="bibr" target="#b113">[112]</ref>.</s><s>Acne treatment guidelines written some years ago advocated the use of oral isotretinoin "sooner rather than later" <ref type="bibr" target="#b114">[113]</ref>.</s><s>It is recognized that reduction in inflammatory acne may prevent the occurrence of clinical and psychological scarring, improving quality of life and in some cases reducing depression <ref type="bibr" target="#b115">[114,</ref><ref type="bibr" target="#b116">115]</ref>.</s><s>Delaying the use of oral isotretinoin, which the group considers to be the most effective treatment for severe acne, poses a significant ethical problem.</s><s>Although comparative trials are missing, clinical experience confirms that the relapse rates after treatment with isotretinoin are the lowest among all the available therapies.</s></p><p><s>Unfortunately the European Directive, although not supported by convincing evidence-based data, reached a different conclusion.</s><s>Theoretically, in EU countries clinicians are free to prescribe drugs, such as oral isotretinoin, according to their professional experience and clinical judgment.</s><s>However, in the event of any medical problems, clinicians could be deemed liable if they have failed to follow recommended prescribing practice <ref type="bibr" target="#b117">[116]</ref>.</s></p><p><s>There are a number of good reasons why systemic isotretinoin should be considered as the first-choice treatment for severe acne, including high levels of clinical effectiveness, prevention of scarring and improvement of a patient's quality of life.</s></p><p><s>The EMA recommendations include the following points:</s></p><p><s>1. To start at the dosage of 0.5 mg/kg daily.</s></p><p><s>2.</s><s>Not recommended for patients under 12 years of age.</s></p><p><s>3. To monitor laboratory parameters, primarily liver enzymes and lipids, before treatment, 1 month after starting and every 3 months thereafter.</s></p><p><s>4. To avoid laser treatment, peeling and wax epilation for at least 6 months after stopping therapy.</s></p><p><s>The European Guideline group supports these recommendations of the EMA, although expert opinion suggests that being less than 12 years old (point 2) is not necessarily a contraindication for the use of isotretinoin.</s></p><p><s>Two areas which are potentially open for future review include dosing regimens and abnormal wound healing as a result of oral isotretinoin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosing regimens</head><p><s>It has been demonstrated that starting with a low dose (0.1-0.2 mg/kg/day) of isotretinoin and progressively increasing to the highest tolerated dose may reduce risk and severity of acne flare-ups and facilitate management of and reduce side effects <ref type="bibr" target="#b118">[117]</ref>.</s><s>Over the last few years there have been an increasing number of reports on oral isotretinoin in more mild to moderate disease in which alternative dosing regimens have aimed to achieve efficacy whilst minimizing side effects from treatment <ref type="bibr" target="#b119">[118]</ref><ref type="bibr" target="#b120">[119]</ref><ref type="bibr" target="#b121">[120]</ref>.</s></p><p><s>In contrast to this other studies have indicated that higher doses, especially in severe nodular/ conglobate acne, are associated with fewer relapse rates <ref type="bibr" target="#b122">[121,</ref><ref type="bibr" target="#b123">122]</ref>.</s><s>Hence, where possible higher dosages are recommended in severe acne and lower dosages in less severe forms and as potential maintenance treatment.</s><s>As differences in pharmacokinetics between different brands of isotretinoin cannot be ruled out it is advisable to get acquainted with a certain product and to use this same preparation throughout a treatment period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abnormal wound healing</head><p><s>Current recommendations to avoid acne scar repair procedures within 6 months post oral isotretinoin arose from reports in the mid 1980's of delayed wound healing and hypertrophic scarring with conventional and argon laser dermabrasion.</s><s>More recent small studies suggest that resurfacing procedures do not always impair wound healing despite treatment being performed during oral isotretinoin treatment or early after cessation of isotretinoin <ref type="bibr" target="#b124">[123]</ref>.</s><s>The results from these studies are confounded by small numbers and information bias (lack of blinding and lack of validated assessments in particular) and a lack of control for confounding variables and selection and publication bias.</s></p><p><s>The group did not identify any evidence to support the avoidance of laser therapy, wax epilation and peeling for at least 6 months after isotretinoin treatment (point 4) <ref type="bibr" target="#b117">[116]</ref>.</s><s>However, the authors acknowledge that oral isotretinoin could interfere with wound healing albeit relatively rare.</s><s>As further evidence emerges recommendations to avoid acne scar repair procedures within 6 months post isotretinoin should be reconsidered.</s><s>Earlier treatment of scarring may provide hope that this issue can be effectively addressed on a timely basis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.5">Consideration on isotretinoin and the risk of depression</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nast</head><p><s>It is recommended to assess prior symptoms of depression as part of the medical history of any patient before the initiation of isotretinoin and during the course of the treatment.</s></p><p><s>It is recommended to inform patients about a possible risk of depression and suicidal behaviour.</s></p><p><s>A search for systematic reviews was performed to assess the risk of depression during the treatment with isotretinoin.</s><s>Published systematic reviews come to different conclusions.</s><s>All currently existing reviews have methodological limitations with respect to their stringency of inclusion and exclusion criteria and systematic reporting of identified studies.</s></p><p><s>The systematic review by Marqueling et al. <ref type="bibr" target="#b125">[124]</ref> reported that rates of depression among isotretinoin users ranged from 1 % to 11 % across trials, with similar rates in the oral antibiotic control groups.</s><s>Overall, included trials comparing depression before and after treatment did not show a statistically significant increase in depression diagnoses or depressive symptoms.</s><s>Some, in fact, demonstrated a trend toward fewer or less severe depressive symptoms after isotretinoin therapy.</s><s>This decrease was particularly evident in patients with pre-treatment scores in the moderate or clinical depression range.</s><s>No correlation between isotretinoin use and suicidal behaviour was reported, although only one retrospective trial presented data on this topic.</s></p><p><s>A systematic review by Bremner et al. <ref type="bibr" target="#b126">[125]</ref> took a variety of aspects into consideration: 1) case reports; 2) temporal association between onset of depression and exposure to the drug; 3) challenge-rechallenge cases; 4) class effect (other compounds in the same class, like vitamin A, having similar neuropsychiatric effects); 5) dose response; and 6) biologically plausible mechanisms.</s><s>It concluded that the literature reviewed is consistent with an association between isotretinoin administration, depression and suicide in some individuals.</s></p><p><s>In the light of continued uncertainty with respect to the isotretinoin, depression and suicidal behavior, caution and patient information appears reasonable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.6">Risk of antibiotic resistance</head><p><s>Simonart/ Ochsendorf/ Oprica/ Lomholt</s></p><p><s>Treatment of acne with longer courses of topical or systemic antibiotics may lead to the induction of antibiotic resistance.</s><s>This may contribute to the burden of extra deaths and hospital days due to antibiotic resistant pathogenic bacteria that poses a serious problem in the world today, including in Europe.</s><s>It is well known that one broad spectrum antibiotic can select for multi-resistance against a number of different antibiotics <ref type="bibr" target="#b127">[126]</ref>.</s><s>Furthermore it has been shown, that even low concentrations of antibiotics well below the MIC value may select for even high-level resistance <ref type="bibr" target="#b128">[127,</ref><ref type="bibr" target="#b129">128]</ref>.</s><s>The use of antibiotics to treat acne may lead to resistance in local P. acnes and other local cutaneous bacteria including staphylococci, but importantly, also in members of the patients total microbiome on skin and mucosal surfaces.</s><s>Resistance may spread from non-pathogenic to pathogenic species.</s></p><p><s>The first relevant changes in P. acnes antibiotic sensitivity were found in the USA shortly after the introduction of the topical formulations of erythromycin and clindamycin.</s><s>The molecular basis of resistance, via mutations in genes encoding 23S and 16S rRNA, are widely distributed <ref type="bibr" target="#b130">[129]</ref>.</s><s>However, the development of strains with still unidentified mutations suggests that new mechanisms of resistance are evolving in P. acnes <ref type="bibr" target="#b130">[129]</ref>.</s><s>Combined resistance to clindamycin and erythromycin is much more common (highest prevalence 91 % in Spain) than resistance to the tetracyclines (highest prevalence 26 % in the UK) <ref type="bibr" target="#b131">[130]</ref>.</s><s>Use of topical antibiotics can lead to resistance largely confined to the skin of treated sites, whereas oral antibiotics can lead to resistance in commensal flora at all body sites <ref type="bibr" target="#b132">[131]</ref>.</s></p><p><s>Resistance is more common in patients with moderate-to-severe acne and in countries with high outpatient antibiotic sales <ref type="bibr" target="#b133">[132]</ref>.</s><s>Resistance is disseminated primarily by person-to-person contact, and so the spread of resistant strains by the treating physicians and by family and friends occurs frequently <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b130">129,</ref><ref type="bibr" target="#b131">130]</ref>.</s></p><p><s>Although some data suggest that resistant isolates disappear after antibiotic treatment is stopped <ref type="bibr" target="#b134">[133,</ref><ref type="bibr" target="#b135">134]</ref>, other data suggest that resistance persists and can be reactivated rapidly <ref type="bibr" target="#b136">[135]</ref>.</s></p><p><s>There has been an increasing number of reports of systemic infections caused by resistant P. acnes in non-acne patients, e. g. post-surgery <ref type="bibr" target="#b133">[132]</ref>.</s><s>In addition, a transmission of factors conferring resistance to bacteria other than P. acnes is described <ref type="bibr" target="#b137">[136,</ref><ref type="bibr" target="#b138">137]</ref>.</s><s>Although antibiotic use in acne patients has been shown to be associated with an increased risk of upper respiratory tract infection and with an increased carriage of S. aureus <ref type="bibr" target="#b139">[138]</ref>, the true clinical importance of these findings requires further investigation.</s></p><p><s>It has been argued that the most likely effect of resistance is to reduce the clinical efficacy of antibiotic-based treatment regimens to a level below that which would occur in patients with fully susceptible flora <ref type="bibr" target="#b131">[130,</ref><ref type="bibr" target="#b140">139]</ref>.</s><s>Some trials have suggested a clear association between P. acnes resistance to the appropriate antibiotic and poor therapeutic response <ref type="bibr" target="#b131">[130,</ref><ref type="bibr" target="#b140">139]</ref>.</s><s>There is a gradual decrease in the efficacy of topical erythromycin in clinical trials of therapeutic intervention for acne, which is probably related to the development of antibiotic-resistant propionibacteria <ref type="bibr" target="#b102">[101]</ref>.</s><s>In contrast, there is so far no evidence that the efficacy of oral tetracycline or topical clindamycin has decreased in the last decades <ref type="bibr" target="#b102">[101,</ref><ref type="bibr" target="#b141">140,</ref><ref type="bibr" target="#b142">141]</ref>.</s><s>However recent studies show a complex population of P. acnes with diverse virulence potential and antibiotic resistance patterns.</s><s>This may explain the difficulties in predicting the clinical effects of antibiotic treatment of acne <ref type="bibr" target="#b143">[142]</ref>.</s></p><p><s>Since P. acnes is the major skin commensal bacterium found in both acne and healthy skin, the strain-level analysis is important to help understand the role of P. acnes in acne pathogenesis and in skin health.</s><s>It has been demonstrated that the strain population subtypes or clonotypes were significantly different in acne patients and healthy controls <ref type="bibr" target="#b86">[85,</ref><ref type="bibr" target="#b89">88]</ref>.</s><s>This data could help determine if therapeutic modulations of the local P. acnes flora can return the host to a state of health and may open for new treatment options.</s></p><p><s>Studies on P. acnes resistance have highlighted the need for treatment guidelines to restrict the use of antibiotics in order to limit the emergence of resistant P. acnes strains.</s><s>Data indicate that the combination of topical antibiotics with BPO may prevent the development of resistance in local P. acnes and staphylococci <ref type="bibr" target="#b144">[143]</ref><ref type="bibr" target="#b145">[144]</ref><ref type="bibr" target="#b146">[145]</ref><ref type="bibr" target="#b147">[146]</ref><ref type="bibr" target="#b148">[147]</ref><ref type="bibr" target="#b149">[148]</ref>.</s><s>However, it is not known if resistance may develop in the periphery or outside the treatment zone due to antibiotic gradients or if a low level of systemic absorption can lead to resistance on mucosal surfaces <ref type="bibr" target="#b150">[149,</ref><ref type="bibr" target="#b151">150]</ref>.</s><s>There is not good evidence that the combination of local antibiotics with retinoids or zinc is efficient to prevent local resistance in P. acnes and no data is available on the effect on other cutaneous or mucosal bacteria <ref type="bibr" target="#b149">[148,</ref><ref type="bibr" target="#b152">[151]</ref><ref type="bibr" target="#b153">[152]</ref><ref type="bibr" target="#b154">[153]</ref><ref type="bibr" target="#b155">[154]</ref>.</s></p><p><s>It is claimed that low dose systemic doxycycline treatment of acne does not induce bacterial resistance <ref type="bibr" target="#b156">[155]</ref>.</s><s>From a microbiological standpoint this is highly surprising and more studies are needed to confirm this.</s><s>In particular one study showed development of resistance in subgingival plaques during low dose doxycycline treatment of periodontidis <ref type="bibr" target="#b157">[156]</ref>.</s></p><p><s>As a consequence, the use of systemic antibiotics and topical antibiotics should be limited (both indication and duration) and topical antibiotics should preferably be used in combination with BPO and avoided as monotherapy.</s><s>Other recommendations include stricter cross-infection control measures when assessing acne in the clinic and combining systemic antibiotic therapy with topical broad-spectrum antibacterial agents, such as BPO <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b54">53,</ref><ref type="bibr" target="#b131">130]</ref>.</s><s>A maintenance treatment, especially for the patients with "particular need for a maintenance treatment" as defined below, is recommended.</s></p><p><s>The low strength of recommendation provided below reflects primarily the lack of good evidence as to which is the best treatment and does not put into question the need for maintenance therapy in general.</s><s>Open recommendation Due to a lack of sufficient evidence, it is currently not possible to make a recommendation for or against maintenance treatment with red light, blue light, IPL, Laser, PDT or oral zinc.</s></p><p><s>Negative recommendation Topical and/or systemic antibiotics as monotherapy or combination therapy are not recommended for maintenance treatment of acne.</s><s>Artificial UV radiation is not recommended for maintenance treatment of acne.</s></p><p><s>1 preference for adapalene over isotretinoin / tretinoin 2 in case of continuing inflammatory lesions 3 refer to national guidelines and EMA recommendations for precautions with respect to risk and duration of hormonal antiandrogens/combined oral contraceptives</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.2">Background</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gollnick/ Dréno</head><p><s>Acne is a chronic inflammatory disease that can persist for a number of years, and is known to have a negative impact on the patients' quality of life.</s><s>Scarring is the most difficult sequela of the disease and has therefore to be avoided by appropriate early intervention using an evidence based treatment strategy.</s><s>Acne has the general tendency to relapse; however, very little data exists regarding the frequency and/or severity and/or velocity of relapses.</s></p><p><s>The strategy for treating acne today includes an induction phase followed by a maintenance phase, and is further supported by adjunctive treatments (light, peeling) and/or cosmetic treatments <ref type="bibr" target="#b158">[157]</ref>.</s></p><p><s>Education about the physiopathology and the treatment procedures of acne can enhance patient adherence to maintenance therapy.</s><s>However, the psychosocial benefits of further reconstituting the skin may be the most compelling reason for consistent maintenance therapy.</s><s>It may also be helpful to explain to patients that acne is often a chronic disease running over years that requires acute and maintenance therapy for sustained remission.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definition of maintenance treatment / goals of maintenance treatment</head><p><s>No standard definition for maintenance treatment exists/is used.</s></p><p><s>The European acne guideline version 2011 stated: 'Maintenance therapy can be defined as the regular use of appropriate therapeutic agents to ensure that acne remains in remission'.</s></p><p><s>Dressler et al. <ref type="bibr" target="#b159">[158]</ref> defined 'maintenance is the treatment period that follows a successful induction therapy at the end of which patients had achieved a pre-defined treatment goal'.</s></p><p><s>The Board of the Global Alliance for better Outcome of Acne (GA) consented the following treatment goals:</s></p><p><s>-prevention of relapse of more than 10-20% of inflammatory lesions -preventing reoccurrence of microcomedones -further improvement of postinflammatory hyperpigmentation and atrophic scarring</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identification of patients with particular need for maintenance treatment</head><p><s>Adapted from a consensus from the Board of the Global Alliance for better Outcome of Acne (GA) the following predictive factors for relapse may serve as criteria to identify patients with particular need for maintenance therapy:</s></p><p><s>-history of severe of acne -repeated relapse in medical history after previous therapy</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pathophysiological considerations for the maintenance phase</head><p><s>It has been shown that microcomedones significantly decrease during the active treatment phase but rebound almost immediately after discontinuation of a topical retinoid <ref type="bibr" target="#b160">[159]</ref>.</s></p><p><s>Therefore, a maintenance therapy to reduce the potential of reoccurring visible lesions should be considered as part of routine care today.</s><s>In particular, inflammatory lesions are the prominent marker to be suppressed by topical or combined topical and systemic treatment as soon as possible.</s><s>They almost develop from the recurrence of microcomedones.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy and safety during maintenance therapies</head><p><s>A systematic review by Dressler et al. <ref type="bibr" target="#b159">[158]</ref> identified four randomized controlled trials and three non-randomized intervention studies on acne maintenance treatment.</s></p><p><s>Three RCTs <ref type="bibr" target="#b161">[160]</ref><ref type="bibr" target="#b162">[161]</ref><ref type="bibr" target="#b163">[162]</ref> evaluated adapalene 0.1% gel QD maintenance treatment compared to placebo over the course of 12, 16 and 24 weeks each.</s><s>The pooled effect of two RCTs evaluating adapalene versus vehicle on 'number of patients maintaining at least 50% improvement achieved in the initial study' was statistically significant based on inflammatory and non-inflammatory lesion count <ref type="bibr" target="#b161">[160,</ref><ref type="bibr" target="#b162">161]</ref>.</s><s>The 24-week open RCT by Zang et al. <ref type="bibr" target="#b163">[162]</ref> also reported a higher mean percentage reduction in total lesion count in the adapalene than in the placebo arm.</s><s>Adapalene showed superior efficacy in maintaining response on NIL and IL compared to placebo/ vehicle.</s></p><p><s>Poulin et al. <ref type="bibr" target="#b164">[163]</ref> assessed the fixed combination adapalene 0.1%/ BPO 2.5% gel QD compared to vehicle QD as maintenance treatment.</s><s>A statistically significant difference was found at 12 and 24 weeks based on inflammatory and noninflammatory lesion count: adapalene/ BPO fixed combination showed superior efficacy on NIL and IL compared to placebo.</s></p><p><s>Reported data on tolerability and safety was limited.</s><s>Tolerability was reported by all authors with mild but mostly no burning / stinging, erythema or dryness <ref type="bibr" target="#b159">[158]</ref>.</s></p><p><s>There is a strong need to develop more standardized study designs to systematically assess maintenance therapy for acne.</s><s>Due to the set inclusion and exclusion criteria, many trials reporting on long maintenance treatment could not be included, mostly due to the lack of a clearly defined minimum treatment goal which defines responders to enter into a maintenance phase.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional clinical trials</head><p><s>Recent clinical trials have in particular looked for the effect of maintenance therapy on microcomedones.</s><s>In one of those controlled trials it could be shown that adapalene and azelaic acid have been equivalent in preventing relapse and suppressing microcomedone recurrence <ref type="bibr" target="#b160">[159,</ref><ref type="bibr" target="#b165">164]</ref>.</s></p><p><s>Some other trials which further confirms maintenance therapy to prevent relapse but could not be included because of the guideline rules and less defined maintenance treatment inclusion criteria in the past (see above) should be mentioned here.</s><s>In a vehicle controlled study by Vender et al. <ref type="bibr" target="#b166">[165]</ref> prevention with tretinoin 0.04% gel (microsphere) against relapse was shown in patients having been before successfully treated by oral isotretinoin.</s><s>In another prospective, randomized, doubleblind and vehicle-controlled study of 30 patients with acne previously treated with isotretinoin a retinoid combination (retinsphere technology Bi-retix) was applied to one side of the face and vehicle was applied to the other, once daily, for 3months.</s><s>The relapse rate was significantly lower on the retinoid-treated side compared to the vehicle-treated side.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.3">Reasoning</head><p><s>Available evidence indicates efficacy of topical retinoids and adapalene/ BPO over vehicle during maintenance treatment.</s></p><p><s>Pathophysiological data supports use of topical retinoids and adapalene based on their shown efficacy on microcomedones.</s></p><p><s>Any use of topical or systemic antibiotics is not recommended on a long-term base / during maintenance therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Duration of long term-treatment</head><p><s>The following maintenance treatment periods can be considered:</s></p><p><s>-3 to 6 months following clearing after interventional treatment phase can be recommended -patients with conglobate acne may need long-term maintenance over 6 to 12 months -acne tarda patients may need individual long-term maintenance over years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclaimer</head><p><s>The development of guidelines is a time and resource intensive process and currently no public funding is available for European guidelines.</s><s>In order to be able to produce high quality guidelines the EDF uses its membership contributions and asks its cooperative partners for support.</s></p><p><s>Corporate partners of the EDF have been asked to contribute towards this work.</s></p><p><s>[insert other companies], [insert other companies], and [insert other companies] have contributed funding for the development of the European evidence-based (S3) guideline for the treatment of acne (update 2016) through an educational grant to the EDF.</s><s>Sponsors had no influence on the content of the guideline.</s><s>Support was given independent of any influence on methods or results.</s><s>Sponsors did not receive any information about methods, group members or likely results.</s><s>The sources of the funding will be disclosed to the members of the group and the users of the guideline after the finalization of the guideline.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8">Supporting information</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>2 low strength of recommendation 3 The</head><label>23</label><figDesc><div><p><s>recommendation for comedonal treatment passed with vote of 60% agreement only, see chapter 5.1 for more details.</s><s>adapalene to be preferred over tretinoin/ isotretinoin (see Chapter 5.4.1) 5 Prescribers of antibiotics should be aware of the potential risk of the development of antibiotic resistances .</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>6</head><label>6</label><figDesc><div><p></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>7 doxycycline</head><label>7</label><figDesc><div><p><s>and lymecycline (see Chapter 5.4.2),</s><s>limited to a treatment period of three months 8 only studies found on systemic AB + adapalene; topical isotretinoin and tretinoin can be considered for combination treatment based on expert opinion 9 indirect evidence from nodular and conglobate acne and expert opinion 10 indirect evidence from severe papulopustular acne 11</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>2 adapalene</head><label>2</label><figDesc><div><p><s>to be preferred over tretinoin/ isotretinoin (see Chapter 5.4.1)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>3 doxycycline 5 only</head><label>35</label><figDesc><div><p><s>and lymecycline (see Chapter 5.4.2),</s><s>limited to a treatment period of three months 4 In case of more widespread disease/ moderate severity, initiation of a systemic treatment can be recommended.</s><s>studies found on systemic AB + adapalene; isotretinoin and tretinoin can be considered for combination treatment based on expert opinion 6 adapalene to be preferred over tretinoin/ isotretinoin (see Chapter 5.4.1) 7 indirect evidence from nodular and conglobate acne and expert opinion 8 indirect evidence from severe papularpustular acne 9</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>3 doxycycline</head><label>3</label><figDesc><div><p><s>and lymecycline (see Chapter 5.4.2),</s><s>limited to a treatment period of three months 4 only studies found on systemic AB + adapalene; isotretinoin and tretinoin can be considered for combination treatment based on expert opinion 5 indirect evidence from nodular and conglobate acne and expert opinion 6 indirect evidence from a study also including chlorhexidin, recommendation additionally based on expert opinion</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>3 doxycycline</head><label>3</label><figDesc><div><p><s>and lymecycline (see Chapter 5.4.2),</s><s>limited to a treatment period of three months 4 only studies found on systemic AB + adapalene; isotretinoin and tretinoin can be considered for combination treatment based on expert opinion 5 indirect evidence from severe papulopustular acne</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Formatted: English (United States) Deleted: 5 . 4 . 2 5. 4 . 4</head><label>54244</label><figDesc><div><p><s>Oral isotretinoin considerations with respect to EMA directive Bettoli/ Layton/ Ochsendorf/ Bukvić Mokos</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>Deleted: n 6</head><label>6</label><figDesc><div><p><s>Maintenance therapySummary of therapeutic recommendations for maintenance therapy with respect to acne type before induction therapy Recommendations are based on available evidence and expert consensus.</s><s>Available evidence and expert voting lead to classification of strength of recommendation.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head>-</head><label></label><figDesc><div><p><s>family history of chronicity of acne/ persisting acne courses -tendency for scarring -time until clearance during interventional treatment -severe seborrhea -early and fast onset courses in young adolescents -early and fast onset of conglobate acne in young adolescents -patients already having the course of acne tarda or persisting adult acne -female patients with endocrinological disturbances (clinical or/and serological).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table of contents 6 Maintenance therapy</head><label></label><figDesc></figDesc><table><row><cell cols="2">List of abbreviations</cell></row><row><cell cols="2">ADR 1 Introduction adverse drug reaction</cell></row><row><cell>BPO CY Nast</cell><cell>benzoyl peroxide cyst</cell></row><row><cell>IL</cell><cell>inflammatory lesions</cell></row><row><cell>IPL</cell><cell>intense pulsed light</cell></row><row><cell>LE</cell><cell>level of evidence</cell></row><row><cell>ne</cell><cell>no evidence</cell></row><row><cell>NIL</cell><cell>non-inflammatory lesions</cell></row><row><cell>NO</cell><cell>nodule</cell></row><row><cell>PDT</cell><cell>photodynamic therapy</cell></row><row><cell>sys.</cell><cell>systemic</cell></row><row><cell>TL</cell><cell>total lesion</cell></row><row><cell>top.</cell><cell>topical</cell></row><row><cell>UV</cell><cell>ultraviolet</cell></row><row><cell>vs.</cell><cell>versus</cell></row></table><note><p><s>.............................................................................................................. 6.1 Recommendations ............................................................................................................ 6.2 Background ....................................................................................................................... 6.3 Reasoning ......................................................................................................................... 7 References .............................................................................................................................. 8 Supporting information ..........................................................................................................</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>Other already existing systems are very difficult to compare with one another.</s><s>The group has tried to map the existing systems to the guidelines' clinical classification.</s></p></div></figDesc><table><row><cell>1. Comedonal acne</cell></row><row><cell>2. Mild -moderate papulopustular acne</cell></row><row><cell>3. Severe papulopustular acne, moderate nodular acne</cell></row><row><cell>4. Severe nodular acne, conglobate acne</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1</head><label>1</label><figDesc><div><p><s>Comparison of different acne assessment scales.</s><s>This is an attempt to approximately map the various published acne classifications to the simple four group classification used in this guideline.</s></p></div></figDesc><table><row><cell>Publication</cell><cell>Comedonal</cell><cell>Mild-</cell><cell>Severe</cell><cell>Severe nodular</cell><cell></cell></row><row><cell></cell><cell>acne</cell><cell>moderate</cell><cell>papulopustular</cell><cell>acne, conglobate</cell><cell></cell></row><row><cell></cell><cell></cell><cell>papulo-</cell><cell>acne,</cell><cell>acne</cell><cell></cell></row><row><cell></cell><cell></cell><cell>pustular acne</cell><cell>moderate</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>nodular acne</cell><cell></cell><cell></cell></row><row><cell cols="2">Pillsbury 1956 [26] -</cell><cell>1 -4</cell><cell>2 -4</cell><cell>2 -4</cell><cell></cell></row><row><cell cols="2">Kligman 1976 [27] 1 = &lt; 10</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell></cell></row><row><cell></cell><cell>2 = 10-25</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>3 = &gt; 25-50</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>4 = &gt; 50</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>(facial</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>comedones)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Michaelsson 1977</cell><cell>-</cell><cell>0 -30</cell><cell>20 -30</cell><cell>20 -&gt;30</cell><cell></cell></row><row><cell>[28]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cook 1979 [24]</cell><cell>0 -1</cell><cell>2 -4</cell><cell>6</cell><cell>8</cell><cell></cell></row><row><cell>Wilson 1980 [29]</cell><cell>0</cell><cell>2 -4</cell><cell>6 -8</cell><cell>8</cell><cell></cell></row><row><cell>Allen 1982 [30]</cell><cell>0 -2</cell><cell>2 -6</cell><cell>6</cell><cell>8</cell><cell></cell></row><row><cell>Burke (Leeds)</cell><cell>0.5</cell><cell>0.75 -2</cell><cell>2 -3</cell><cell>3 -8</cell><cell></cell></row><row><cell>1984 [5]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pochi 1991 [23]</cell><cell>Mild</cell><cell cols="2">Mild/moderate Moderate</cell><cell>Severe</cell><cell></cell></row><row><cell>O'Brien (Leeds)</cell><cell>1 -3</cell><cell>4 -7</cell><cell>8 -10</cell><cell>11 -12,</cell><cell></cell></row><row><cell>1998 (face) [19]</cell><cell></cell><cell></cell><cell></cell><cell>nodulocystic</cell><cell></cell></row><row><cell>Dreno 1999 [20]</cell><cell>F1R1 -5</cell><cell>F1Is1 -4</cell><cell>F1Is4 -5,</cell><cell>F1Ip 4 -5</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>F1Ip 1 -4</cell><cell></cell><cell></cell></row><row><cell cols="2">Lehmann 2002 [9] Mild</cell><cell cols="2">Mild/moderate Severe</cell><cell>Severe</cell><cell></cell></row><row><cell cols="2">Gollnick 2003 [13] Mild</cell><cell>Mild papular-</cell><cell>Moderate</cell><cell>Severe nodular/</cell><cell></cell></row><row><cell></cell><cell>comedonal</cell><cell>pustular,</cell><cell>nodular</cell><cell>conglobate</cell><cell></cell></row><row><cell></cell><cell></cell><cell>moderate</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>papular-</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>pustular</cell><cell></cell><cell></cell><cell>Formatted: Spanish (Spain)</cell></row><row><cell>FDA's IGA for</cell><cell>1 Almost</cell><cell>2 Mild: some</cell><cell>3 Moderate:</cell><cell>4 Severe: up to</cell><cell>Formatted: Spanish (Spain)</cell></row><row><cell>acne vulgaris</cell><cell>clear: rare</cell><cell>NIL but no</cell><cell>many NIL, some</cell><cell>many non-</cell><cell>Formatted: Spanish (Spain)</cell></row><row><cell>(2005) [18]</cell><cell>NIL with no</cell><cell>more than a</cell><cell>IL no more than</cell><cell>inflammatory and</cell><cell>Field Code Changed</cell></row><row><cell></cell><cell>more than 1</cell><cell>few papule/</cell><cell>1 nodule</cell><cell>inflammatory</cell><cell>Field Code Changed</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2</head><label>2</label><figDesc><div><p><s>Acne scare severity grading systems</s></p></div></figDesc><table><row><cell></cell><cell>30 for each</cell><cell>Face, chest and back</cell></row><row><cell></cell><cell>region)</cell><cell></cell></row><row><cell>Cicatrices d'Acne [61] Echelle d'Evaluation Clinique des</cell><cell>Numeric (maximum 540)</cell><cell>Face</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>3 Epidemiology and pathophysiology 3.1 Epidemiology Degitz/ Ochsendorf</head><label></label><figDesc></figDesc><table><row><cell>Acne is regarded as one of the most frequent skin diseases. Epidemiologic studies in</cell></row><row><cell>Western industrialized countries estimated the prevalence of acne in adolescents to</cell></row><row><cell>be between 50% and 95%. If mild manifestations were excluded and only moderate</cell></row><row><cell>or severe manifestations were considered, the frequency was still 20% -35% [66-69].</cell></row><row><cell>Acne is a disease primarily of adolescence. It is triggered in children by the initiation</cell></row><row><cell>of androgen production by the adrenal glands and gonads. It may begin as early as</cell></row><row><cell>age 7-9</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 3 Efficacy: Comedonal acne -top. therapy vs. vehicle/ top. therapy</head><label>3</label><figDesc></figDesc><table><row><cell></cell><cell cols="3">Vehicle (v) Azelaic acid (aa) Adapalene (a) Isotretinoin (i)</cell><cell>Tretinoin (t)</cell></row><row><cell>BPO</cell><cell>BPO &gt; v LE 1</cell><cell>BPO &gt; aa LE 4</cell><cell>BPO = a LE 1</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 4 Efficacy: Comedonal acne -top. antibiotics vs. vehicle/ BPO/ azelaic acid/ top. Retinoids</head><label>4</label><figDesc></figDesc><table><row><cell></cell><cell>Vehicle (v)</cell><cell>BPO</cell><cell>Azelaic acid (aa)</cell><cell>Adapalene (a)</cell><cell>Isotretinoin (i)</cell><cell>Tretinoin (t)</cell></row><row><cell>Clindamycin (c)</cell><cell>c &gt; v LE 2</cell><cell>BPO ≥ c LE 1</cell><cell>aa ≥ c LE 4*</cell><cell>ne</cell><cell>ne</cell><cell>t = c LE 3</cell></row><row><cell>Erythromycin (e)</cell><cell>e ≥ v LE 1</cell><cell>ne</cell><cell>aa = e LE 4</cell><cell>ne</cell><cell>e = i LE 3</cell><cell>ne</cell></row><row><cell>Nadifloxacin (n)</cell><cell>n &gt; v LE 4</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Tetracycline (t)</cell><cell>ne</cell><cell>BPO &gt; t LE 3</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell cols="4">LE=level of evidence; ne=no evidence; top.=topical</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">* azelaic acid 15% &gt; clindamycin 1% (LE 4); clindamycin 1% = azelaic acid 5% (LE 4)</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 5 Efficacy: Comedonal acne -top. combination therapy vs. top. therapy/ combinations</head><label>5</label><figDesc></figDesc><table><row><cell>Vehicle (v)</cell><cell>BPO</cell><cell>Adapa-lene (a)</cell><cell>Iso-treti-noin (i)</cell><cell>Treti-noin (t)</cell><cell>Clin-da-mycin (c)</cell><cell>Ery-thro-mycin (e)</cell><cell>Adapa-lene-BPO (a-BPO)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_11"><head>Table 6</head><label>6</label><figDesc><div><p><s>Efficacy: Papulopustular acne -top.</s><s>therapy vs. vehicle/ top.</s><s>therapy</s></p></div></figDesc><table><row><cell></cell><cell cols="4">Vehicle (v) Azelaic acid (aa) Adapalene (a) Isotretinoin (i)</cell><cell>Tretinoin (t)</cell></row><row><cell>BPO</cell><cell>BPO &gt; v LE 1</cell><cell>BPO = aa LE 2</cell><cell>BPO = a LE 1</cell><cell>BPO &gt; i LE 3</cell><cell>conflicting LE 4*</cell></row><row><cell>Azelaic acid (aa)</cell><cell>aa &gt; v LE 1</cell><cell>X</cell><cell>aa = a LE 4</cell><cell>ne</cell><cell>t &gt; aa LE 4</cell></row><row><cell>Adapalene (a)</cell><cell>a &gt; v LE 1**</cell><cell>X</cell><cell>X</cell><cell>i = a LE 4</cell><cell>a = t LE 2-4***</cell></row><row><cell>Isotretinoin (i)</cell><cell>i &gt; v LE 1</cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>i = t LE 4</cell></row><row><cell>Tretinoin (t)</cell><cell>t &gt; v LE 1</cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>X</cell></row><row><cell cols="3">LE=level of evidence; ne=no evidence; top.=topical</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">* tretinoin 0.025% &gt; BPO 5% (LE 4); BPO 5% &gt; tretinoin 0.1% (LE 4); BPO 5-10% = tretinoin 0.05%</cell></row><row><cell>(LE 4)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>** adapalene 0.1% &gt; placebo/vehicle (LE 1); adapalene 0.3% &gt; placebo/vehicle (LE 1) *** adapalene 0.1% = tretinoin 0.025% (LE 2); tretinoin 0.05% &gt; adapalene 0.1% (LE 4); TMG 0.1% = adapalene 0.1%(LE 3)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_12"><head>Table 7</head><label>7</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Deleted: Table 5</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Deleted: Table 9</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Deleted: 5</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Formatted: French (France)</cell></row><row><cell cols="11">Efficacy: Papulopustular acne -top. combination therapy vs. top. therapy/</cell><cell>Deleted: 6</cell></row><row><cell cols="2">combinations</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Vehicle (v)</cell><cell>BPO</cell><cell>Ada-palene (a)</cell><cell>Iso-treti-noin (i)</cell><cell>Tre-tino-in (t)</cell><cell>Clin-damy-cin (c)</cell><cell>Ery-thro-mycin (e)</cell><cell>Adapa-lene-BPO (a-BPO)</cell><cell>BPO-clinda-mycin (c-BPO)</cell><cell>Clinda-mycin-tretino-in (ct)</cell></row><row><cell>Adapale-</cell><cell>a-BPO</cell><cell>a-BPO</cell><cell>a-BPO</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ne-BPO</cell><cell>&gt; v</cell><cell>= BPO</cell><cell>&gt; a</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>X</cell><cell>X</cell><cell>X</cell></row><row><cell>(a-BPO)</cell><cell>LE 1</cell><cell>LE 3</cell><cell>LE 1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>BPO-clindamy-cin (BPO-c)</cell><cell>BPO-c &gt; v LE 1</cell><cell>BPO-c &gt; BPO LE 4</cell><cell>BPO-c &gt; a LE 3</cell><cell>ne</cell><cell>ne</cell><cell>BPO-c &gt; c LE 1</cell><cell>ne</cell><cell>BPO-c LE 4* = a-BPO</cell><cell>X</cell><cell>X</cell></row><row><cell>Clinda-mycin-tretinoin (ct)</cell><cell>ct &gt; v LE 1</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ct &gt; t LE 1</cell><cell>ct = c LE 2</cell><cell>ne</cell><cell>ne</cell><cell>BPO-c LE 4 = ct</cell><cell>X</cell></row><row><cell>Clindamy-cin-zinc (cz)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>cz = c LE 3</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Erythro-mycin -isotretino-</cell><cell>ei &gt; v LE 3</cell><cell>ne</cell><cell>ne</cell><cell>ei &gt; i LE 3</cell><cell>ne</cell><cell>ne</cell><cell>ei = e LE 3</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_13"><head>Table 8</head><label>8</label><figDesc><div><p><s>Efficacy: Papulopustular acne -top.</s><s>therapy vs. sys.</s><s>therapy</s></p></div></figDesc><table><row><cell></cell><cell>Isotretinoin</cell><cell>Clindamycin/ erythromycin/ lymecycline</cell><cell>Tetracycline (t)</cell><cell>Doxycycline (d)</cell><cell>Minocycline (m)</cell></row><row><cell>Azelaic acid (aa)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>BPO</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>BPO = m LE 3</cell></row><row><cell>Clindamycin (c)</cell><cell>ne</cell><cell>ne</cell><cell>c = t LE 1</cell><cell>ne</cell><cell>c &gt; m LE 4</cell></row><row><cell>Erythromycin (e) Erythromycin+ zinc (ez)</cell><cell>ne ne</cell><cell>ne ne</cell><cell>e &gt; t LE 3 ez ≥ t LE 3*</cell><cell>ne ne</cell><cell>ne ez &gt; m LE 4</cell></row><row><cell>Tetracycline (t)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row></table><note><p><s>LE=level of evidence; ne=no evidence; sys.=systemic; top.=topical*</s><s>erythromycin + zinc liquid &gt; sys.tetracycline (LE 3); erythromycin + zinc gel &gt; sys.tetracycline(LE 3)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_14"><head>Table 9</head><label>9</label><figDesc></figDesc><table><row><cell cols="9">Efficacy: Papulopustular acne -sys. monotherapy vs. antibiotics/ isotretinoin/</cell></row><row><cell>zinc</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Placebo/</cell><cell>Doxycy-</cell><cell>Erythro-</cell><cell>Lymecy-</cell><cell>Minocy-</cell><cell>Tetracy-</cell><cell>Isotre-</cell><cell>Zinc</cell></row><row><cell></cell><cell>vehicle (v)</cell><cell>cline (d)</cell><cell>mycin (e)</cell><cell>cline (l)</cell><cell>cline (m)</cell><cell>cline (t)</cell><cell>tinoin (i)</cell><cell>(z)</cell></row><row><cell>Clindamycin (c)</cell><cell>c &gt; v LE 3</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>t &gt; c LE 3</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Doxycycline (d)</cell><cell>conflicting LE 3*</cell><cell>X</cell><cell>e = d LE 3</cell><cell>ne</cell><cell>m = d LE 3</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Erythro-mycin (e)</cell><cell>ne</cell><cell>X</cell><cell>X</cell><cell>ne</cell><cell>ne</cell><cell>e = t LE 3</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Lymecycline</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_16"><head>Table 10</head><label>10</label><figDesc><div><p><s>Efficacy: Papulopustular acne -sys.</s><s>therapy vs. sys.-top.</s><s>combination</s></p></div></figDesc><table /><note><p><s>f.c.=fixed combination, LE=level of evidence; ne=no evidence; sys.=systemic; top.=topical</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_17"><head>Table 10 Deleted : Table 13</head><label>10:13</label><figDesc><div><p><s>to Table14for summary of safety/ tolerability data.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Deleted: 9</cell></row><row><cell></cell><cell>Isotretinoin</cell><cell>Clindamy-</cell><cell>Doxycycline</cell><cell>Lymecy-</cell><cell>Tetracy-</cell><cell></cell></row><row><cell></cell><cell>(i)</cell><cell>cin (c)</cell><cell>(d)</cell><cell>cline (l)</cell><cell>cline (t)</cell><cell></cell></row><row><cell>Top. adapalene + sys. doxycycline (a-d)</cell><cell>ne</cell><cell>ne</cell><cell>a-d = d LE 4</cell><cell>ne</cell><cell>ne</cell><cell></cell></row><row><cell>Top. adapalene + BPO (f.c.) + sys. doxycycline (a-BPO-d)</cell><cell>a-BPO-d = i LE 4</cell><cell>ne</cell><cell>d-a-BPO &gt; d LE 3</cell><cell>ne</cell><cell>ne</cell><cell>Formatted: French (France)</cell></row><row><cell>Top. adapalene + sys. tetracycline (ta-t)</cell><cell>i &gt; ta-t LE 4</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell></cell></row><row><cell>Top. adapalene + sys. lymecycline (a-l)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>a-l &gt; l LE 4</cell><cell>ne</cell><cell></cell></row><row><cell>Top. azelaic acid + sys. minocycline (aa-m)</cell><cell>aa-m = i LE 4</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell></cell></row><row><cell>Top. tetracycline + sys. tetracycline (t-t)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Deleted:</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_18"><head>Table 11</head><label>11</label><figDesc><div><p><s>Safety/ tolerability: Papulopustular acne -top.</s><s>therapy vs. top.</s><s>therapy</s></p></div></figDesc><table><row><cell></cell><cell cols="3">Azelaic acid (aa) Adapalene (a) Isotretinoin (i)</cell><cell>Tretinoin (t)</cell></row><row><cell>BPO</cell><cell>aa &gt; BPO LE 4</cell><cell>BPO = a LE 4</cell><cell>BPO = i LE 4</cell><cell>BPO = t LE 4 / insufficient data*</cell></row><row><cell>Azelaic acid (aa)</cell><cell>X</cell><cell>aa &gt; a LE 4</cell><cell>ne</cell><cell>aa &gt; t LE 4</cell></row><row><cell>Adapalene (a)</cell><cell>X</cell><cell>X</cell><cell>a &gt; i LE 4</cell><cell>a &gt; t LE 4**</cell></row><row><cell>Isotretinoin (i)</cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>insufficient data</cell></row><row><cell cols="3">LE=level of evidence; ne=no evidence; top.=topical</cell><cell></cell><cell></cell></row><row><cell cols="5">* tretinoin 0.025% = BPO 5% (LE 4); BPO 5% vs. tretinoin 0.1% (insufficient data); BPO 5-10% vs.</cell></row><row><cell cols="2">tretinoin 0.05% (insufficient data)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">** adapalene 0.1% &gt; tretinoin 0.025% (LE 4); adapalene 0.1% &gt; tretinoin 0.05% (LE 4); adapalene</cell></row><row><cell cols="2">0.1% &gt; TMG 0.1% (LE 4)</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_19"><head>Table 12</head><label>12</label><figDesc></figDesc><table><row><cell cols="10">Safety/ tolerability: Papulopustular acne -top. combinations vs. top.</cell></row><row><cell cols="3">therapy/ combinations</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>BPO</cell><cell>Ada-palene (a)</cell><cell>Iso-tre-tinoin (i)</cell><cell>Treti-noin (t)</cell><cell>Clinda-mycin (c)</cell><cell>Ery-thro-mycin (e)</cell><cell>Adapa-le-ne-BPO (a-BPO)</cell><cell>BPO-clinda-mycin (BPO-c)</cell><cell>Clinda-mycin-tretinoin (ct)</cell></row><row><cell>Adapalene-BPO (a-BPO)</cell><cell>BPO &gt; LE 1 a-BPO</cell><cell>a &gt; a-LE 4 BPO</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>X</cell><cell>X</cell><cell>X</cell></row><row><cell>BPO-</cell><cell>BPO-c</cell><cell>BPO-c</cell><cell></cell><cell></cell><cell>BPO-c</cell><cell></cell><cell>BPO-c &gt;</cell><cell></cell><cell></cell></row><row><cell>clindamycin</cell><cell>= BPO</cell><cell>&gt; a</cell><cell>ne</cell><cell>ne</cell><cell>= c</cell><cell>ne</cell><cell>a-BPO</cell><cell>X</cell><cell>X</cell></row><row><cell>(BPO-c)</cell><cell>LE 1</cell><cell>LE 4</cell><cell></cell><cell></cell><cell>LE 1</cell><cell></cell><cell>LE 4*</cell><cell></cell><cell></cell></row><row><cell>Clindamycin-tretinoin (ct)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>t = ct LE 4</cell><cell>c &gt; ct LE 1</cell><cell>ne</cell><cell>ne</cell><cell>BPO-c = LE 4 ct</cell><cell>X</cell></row><row><cell>Clindamyin-zinc (cz)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>cz = c LE 4</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Erythromycin-isotretinoin (ei)</cell><cell>ne</cell><cell>ne</cell><cell>ei = i LE 4</cell><cell>ne</cell><cell>ne</cell><cell>ei = e LE 4</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Erythromycin-tretinoin (et)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Erythromycin-zinc (ez)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ez = c LE 4</cell><cell>e &gt; ez LE 4</cell><cell>ne</cell><cell>BPO-c = LE 4 ez</cell><cell>ne</cell></row><row><cell cols="5">LE=level of evidence; ne=no evidence; top.=topical</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="9">* clindamycin-BPO &gt; adapalene-BPO after 12 weeks of treatment (LE 4); clindamycin-BPO &gt;</cell><cell></cell></row><row><cell cols="5">adapalene-BPO after 2 weeks of treatment (LE 4)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="7">Topical monotherapy versus systemic monotherapy</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="10">Topical treatments usually result in local side effects whereas systemic treatments</cell></row><row><cell cols="10">cause, among others, mostly gastrointestinal effects. It is therefore difficult to</cell></row><row><cell cols="10">accurately compare topical and systemic treatments in terms of safety/ tolerability.</cell></row></table><note><p><s>Deleted: 10 Formatted: French (France) Deleted: 11 Formatted: French (France)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_20"><head>Table 13</head><label>13</label><figDesc></figDesc><table><row><cell></cell><cell cols="7">Safety/ tolerability: Papulopustular acne -sys. monotherapy vs. sys.</cell></row><row><cell cols="3">antibiotics/ isotretinoin/ zinc</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Doxycy-cline (d)</cell><cell>Erythro-mycin (e)</cell><cell>Lymecy-cline (l)</cell><cell>Minocy-cline (m)</cell><cell>Tetracy-cline (t)</cell><cell>Isotreti-noin (i)</cell><cell>Zinc (z)</cell></row><row><cell>Clinda-mycin (c)</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell><cell>t = c LE 4</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Doxycy-cline (d)</cell><cell>X</cell><cell>insufficient data</cell><cell>ne</cell><cell>m = d LE 4</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Erythro-mycin (e)</cell><cell>X</cell><cell>X</cell><cell>ne</cell><cell>ne</cell><cell>t &gt; e LE 4</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Lymecy-cline (l)</cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>l &gt; m LE 4</cell><cell>ne</cell><cell>ne</cell><cell>ne</cell></row><row><cell>Minocy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_21"><head>Table 14</head><label>14</label><figDesc></figDesc><table><row><cell cols="5">Safety/ tolerability: Papulopustular acne -sys.-top. combination vs. sys.</cell></row><row><cell>therapy</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Isotretinoin (i)</cell><cell>Clinda-mycin (c)</cell><cell>Doxycycline (d)</cell><cell>Lymecy-cline (l)</cell><cell>Tetra-cycline (t)</cell></row></table><note><p><s>f.c.=fixed combination, LE=level of evidence; ne=no evidence; sys.=systemic; top.=topical</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_22"><head>Table 15</head><label>15</label><figDesc></figDesc><table><row><cell cols="2">Efficacy: Nodular/ conglobate acne</cell><cell></cell></row><row><cell></cell><cell cols="2">Sys. isotretinoin (si) Sys. tetracycline (st)</cell></row><row><cell>Adapalene + tetracycline (a-t)</cell><cell>si = a-t LE 4</cell><cell>ne</cell></row><row><cell>Azelaic acid + minocycline (aa-m)</cell><cell>si = aa-m LE 4</cell><cell>ne</cell></row><row><cell>Sys. tetracycline (st)</cell><cell>si &gt; st LE 3</cell><cell>X</cell></row><row><cell>Top. clindamycin (tc)</cell><cell>ne</cell><cell>st &gt; tc LE 3</cell></row></table><note><p><s>LE=level of evidence; ne=no evidence; sys.=systemic; top.=topical</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_23"><head>moderate nodular acne and severe nodular/ conglobate acne</head><label></label><figDesc><div><p><s>The fixed-dose combination adapalene and BPO 2 can be considered for the maintenance treatment of severe papulopustular/ moderate nodular acne and severe nodular/ conglobate acne.Azelaic acid can be considered for the maintenance treatment of severe papulopustular/ moderate nodular acne and severe nodular/ conglobate acne.BPO 2 can be considered for the maintenance treatment of severe papulopustular/ moderate nodular acne and severe nodular/ conglobate acne.Low dose systemic isotretinoin (max.0.3 mg/kg/d) can be considered for the maintenance treatment of severe papulopustular/ moderate nodular acne and severe nodular/ conglobate acne.Topical retinoid 1 can be considered for the maintenance treatment of severe papulopustular/ moderate nodular acne and severe nodular/ conglobate acne.For females: Continued hormonal antiandrogens3and topical treatment (apart from antibiotics) can be considered for the maintenance treatment of severe papulopustular/ moderate nodular acne and severe nodular/ conglobate acne.</s></p></div></figDesc><table><row><cell cols="2">None</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">Low strength of recommendation</cell><cell></cell></row><row><cell cols="2">Comedonal acne</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">Azelaic acid can be considered for the maintenance treatment of comedonal acne.</cell></row><row><cell cols="6">Topical retinoid 1 can be considered for the maintenance treatment of comedonal</cell></row><row><cell cols="2">acne.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">Mild to moderate papulopustular acne</cell><cell></cell></row><row><cell cols="6">Azelaic acid can be considered for the maintenance treatment of mild to moderate</cell></row><row><cell cols="2">papulopustular acne.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">Topical retinoid 1 can be considered for the maintenance treatment of mild to</cell></row><row><cell cols="4">moderate papulopustular acne.</cell><cell></cell></row><row><cell cols="3">Severe papulopustular/</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Comedonal</cell><cell>Mild to</cell><cell>Severe</cell><cell>Severe nodular/</cell></row><row><cell></cell><cell>acne</cell><cell></cell><cell>moderate</cell><cell>papulopustular/</cell><cell>conglobate acne</cell></row><row><cell></cell><cell></cell><cell></cell><cell>papulopustular</cell><cell>moderate nodular</cell></row><row><cell></cell><cell></cell><cell></cell><cell>acne</cell><cell>acne</cell></row><row><cell cols="2">High strength of recommendation</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell cols="2">Medium strength</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">of recommen-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell cols="2">dation</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Low strength of</cell><cell></cell><cell></cell><cell>Adapalene + BPO</cell><cell>Adapalene + BPO</cell></row><row><cell cols="2">recommendation</cell><cell></cell><cell></cell><cell>(f.c.) 3</cell><cell>(f.c.) 3</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>or</cell><cell>or</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Azelaic Acid</cell><cell>Azelaic Acid</cell><cell>Azelaic Acid</cell></row><row><cell></cell><cell cols="2">Azelaic Acid</cell><cell>or</cell><cell>or</cell><cell>or</cell></row><row><cell></cell><cell></cell><cell>or</cell><cell>BPO</cell><cell>BPO 3</cell><cell>BPO 3</cell></row><row><cell></cell><cell cols="2">Topical</cell><cell>or</cell><cell>or</cell><cell>or</cell></row><row><cell></cell><cell cols="2">Retinoid 2</cell><cell>Topical Retinoid</cell><cell>Low Dose Systemic</cell><cell>Low Dose Systemic</cell></row><row><cell></cell><cell></cell><cell></cell><cell>2</cell><cell>Isotretinoin</cell><cell>Isotretinoin</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(max. 0.3mg/kg/d)</cell><cell>(max. 0.3mg/kg/d)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>or</cell><cell>or</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Topical Retinoid 2</cell><cell>Topical Retinoid 2</cell></row><row><cell cols="2">Alternatives for</cell><cell></cell><cell></cell><cell>Continued Hormonal</cell><cell>Continued Hormonal</cell></row><row><cell cols="2">females 1</cell><cell></cell><cell></cell><cell>Antiandrogens 4 +</cell><cell>Antiandrogens 4 +</cell></row><row><cell></cell><cell></cell><cell>-</cell><cell>-</cell><cell>Topical Treatment</cell><cell>Topical Treatment</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(apart from</cell><cell>(apart from</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>antibiotics)</cell><cell>antibiotics)</cell></row><row><cell>1</cell><cell cols="2">low strength of recommendation</cell><cell></cell><cell></cell></row><row><cell>2</cell><cell cols="3">preference for adapalene over isotretinoin / tretinoin</cell><cell></cell></row><row><cell>3</cell><cell cols="3">in case of continuing inflammatory lesions</cell><cell></cell></row><row><cell>4</cell><cell cols="5">refer to national guidelines and EMA recommendations for precautions with respect to risk and durat ion of</cell></row><row><cell></cell><cell cols="3">hormonal antiandrogens/combined oral contraceptives</cell><cell></cell></row><row><cell cols="3">6.1 Recommendations</cell><cell></cell><cell></cell></row><row><cell cols="4">High strength of recommendation</cell><cell></cell></row><row><cell cols="2">None</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">Medium strength of recommendation</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Formatted: French (France)</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines. Clinical practice guidelines: directions for a new program</title>
		<author>
			<persName><forename type="first">M</forename><surname>Field</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Lohr</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1990">1990</date>
			<publisher>National Academy Press</publisher>
			<pubPlace>Washington, D.C</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">The acnes. London. Martin Dunitz Ltd</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Pathogenesis of acne</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shuster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="685" to="687" />
			<date type="published" when="1969">1969</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Lucky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Biro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Huster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Leach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ratterman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="308" to="314" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The assessment of acne vulgaris--the Leeds technique</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="83" to="92" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The natural evolution of comedones into inflammatory papules and pustules</title>
		<author>
			<persName><forename type="first">N</forename><surname>Orentreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Durr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="316" to="320" />
			<date type="published" when="1974">1974</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">The International League of Dermatological Societies&apos; Revised Glossary for the Description of Cutaneous Lesion</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cem</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sterry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bolognia</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note>under review</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Acne analysis, grading and computational assessment methods: an overview</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ramli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Malik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Hani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jamil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Skin Res Technol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Acne therapy: a methodologic review</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Lehmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Holloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Goodman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="231" to="240" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Outcome measures in acne vulgaris: systematic review</title>
		<author>
			<persName><forename type="first">H</forename><surname>Barratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Car</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lyons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Layton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Majeed</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="132" to="136" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The assessment of acne: an evaluation of grading and lesion counting in the measurement of acne</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Witkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Parish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Dermatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="394" to="397" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group</title>
		<author>
			<persName><forename type="first">D</forename><surname>Thiboutot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bettoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Leyden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="S1" to="50" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Management of acne: a report from a Global Alliance to Improve Outcomes in Acne</title>
		<author>
			<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Berson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Leyden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="S1" to="37" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Acne severity grading: determining essential clinical components and features using a Delphi consensus</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wolfe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Stein-Gold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Rosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="187" to="193" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Auto-classification of acne lesions using multimodal imaging</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Patwardhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Kaczvinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Joa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Canfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Drugs Dermatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="746" to="756" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">How people with acne decide whether their treatment is working</title>
		<author>
			<persName><forename type="first">K</forename><surname>Warburton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Whitehouse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>El-Naes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Eady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Layton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A multirater validation study to assess the reliability of acne lesion counting</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Lucky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Barber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Girman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ratterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waldstreicher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="559" to="565" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">S</forename></persName>
		</author>
		<ptr target="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071292.pdf" />
		<imprint>
			<date type="published" when="2005">2005. 2015</date>
		</imprint>
	</monogr>
	<note>Last accessed: 21</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The Leeds revised acne grading system</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatolog Treat</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="215" to="220" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bodokh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chivot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Humbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Poli</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>ECLA grading: a system of acne classification for every day dermatological practice</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="136" to="141" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alirezai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Auffret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Beylot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chivot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Daniel</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Clinical and psychological correlation in acne: use of the ECLA and CADI scales</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="451" to="455" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Savory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Agim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maldonado</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="108" to="114" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Pochi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Shalita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Strauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Webster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">of the Consensus Conference on Acne Classification</title>
				<meeting><address><addrLine>Washington, D.C.</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1990">March 24 and 25. 1990. 1991</date>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="495" to="500" />
		</imprint>
	</monogr>
	<note type="report_type">Report</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">An acne grading method using photographic standards</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Centner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Michaels</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="571" to="575" />
			<date type="published" when="1979">1979</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Development and validation of a comprehensive acne severity scale</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sapra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cutan Med Surg</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="211" to="216" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Acne, acneform eruptions and rosacea</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Pillsbury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Shelley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Kligman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology. Philadelphia. Saunders</title>
		<editor>Pillsbury DM, Shelley WB, Kligman AM</editor>
		<imprint>
			<biblScope unit="page" from="8004" to="8027" />
			<date type="published" when="1956">1956</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Classification of acne</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Kligman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Plewig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cutis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="520" to="522" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Effects of oral zinc and vitamin A in acne</title>
		<author>
			<persName><forename type="first">G</forename><surname>Michaelsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Juhlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vahlquist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="31" to="36" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Office application of a new acne grading system</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cutis</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="62" to="64" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Various parameters for grading acne vulgaris</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jr</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="23" to="25" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance</title>
		<author>
			<persName><forename type="first">Del</forename><surname>Rosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Q</forename><surname>Bikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hawkes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Benes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Drugs Dermatol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="597" to="600" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Acne Study G. Establishment of grading criteria for acne severity</title>
		<author>
			<persName><forename type="first">N</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Akamatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kawashima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="255" to="260" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">Disorders of the Sebaceous Glands</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Layton</surname></persName>
		</author>
		<editor>Burns T, Breathnach S, Cosx N, Griffiths C</editor>
		<imprint>
			<date type="published" when="2010">2010</date>
			<publisher>Wiley-Blackwell</publisher>
			<biblScope unit="page" from="38" to="39" />
			<pubPlace>Oxford</pubPlace>
		</imprint>
	</monogr>
	<note>Rook&apos;s Textbook of Dermatology. 8th ed</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Poli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pawin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Beylot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Faure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chivot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="43" to="48" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Psychological assessment of skin disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Layton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Interfaces Dermatol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="37" to="39" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Which factors influence quality of life in acne patients?</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zauli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Caracciolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Borghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ricci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Giari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Virgili</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="46" to="50" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">How much disability is caused by acne?</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="194" to="198" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Practical use of a disability index in the routine management of acne</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Gupta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="451" to="456" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Health-related quality of life among patients with facial acne --assessment of a new acne-specific questionnaire</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Lookingbill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Botek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Light</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thiboutot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Girman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="380" to="385" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Condensation and validation of a 4-item index of the Acne-QoL</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Fung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1203" to="1210" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Development of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS)</title>
		<author>
			<persName><forename type="first">Alexis</forename><forename type="middle">A</forename><surname>Daniels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pompilus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Burgess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Drugs Dermatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="333" to="340" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Validation of a New Patient-Reported Outcome Measure for Facial Acne: The Acne Symptom and Impact Scale (ASIS)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hudgens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Daniels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Banderas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Varon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Alexis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Drugs Dermatol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="552" to="559" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Basra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fenech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Gatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Salek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="997" to="1035" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Khan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="210" to="216" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Translating the science of quality of life into practice: What do dermatology life quality index scores mean?</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Hongbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Salek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="659" to="664" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The Children&apos;s Dermatology Life Quality Index (CDLQI): initial validation and practical use</title>
		<author>
			<persName><forename type="first">Lewis-Jones Ms</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="942" to="949" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Acne vulgaris and the quality of life of adult dermatology patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lasek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Chren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="454" to="458" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">The quality of life in acne: a comparison with general medical conditions using generic questionnaires</title>
		<author>
			<persName><forename type="first">E</forename><surname>Mallon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Newton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Klassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Stewart-Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="672" to="676" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Basra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sue-Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="528" to="538" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The development and validation of the Family Reported Outcome Measure (FROM-16)(c) to assess the impact of disease on the partner or family member</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Golics</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Basra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Salek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="317" to="326" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">The role of inflammation in the pathogenesis of acne and acne scarring</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Jeremy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Cutan Med Surg</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="79" to="83" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bettoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ochsendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Perez-Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mobacken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Degreef</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Dermatol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="565" to="571" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">A clinical evaluation of acne scarring and its incidence</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Layton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="303" to="308" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Atrophic acne scars may arise from both inflammatory and non-inflammatory acne lesions</title>
		<author>
			<persName><forename type="first">M</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Antony</forename><forename type="middle">A</forename><surname>Do</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hinds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sachs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Voorhees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="page">S58</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Classification of acne scars is difficult even for acne experts</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bettoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Goh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="391" to="393" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Clinical morfology and ultrasound correlation in the assessment of acne scars</title>
		<author>
			<persName><forename type="first">G</forename><surname>Micali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tedeschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lacarrubba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Francesconi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="page">B17</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Selective nonablative treatment of acne scarring with 585 nm flashlamp pulsed dye laser</title>
		<author>
			<persName><forename type="first">N</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Clement</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatol Surg</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="942" to="945" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>discussion 5</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Concurrent use of laser skin resurfacing and punch excision in the treatment of facial acne scarring</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Grevelink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>White</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatol Surg</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="527" to="530" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Comparison of a 1450-nm diode laser and a 1320-nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Tanzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Alster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatol Surg</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="152" to="157" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">ECCA grading scale: an original validated acne scar grading scale for clinical practice in dermatology</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khammari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Orain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Noray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Merial-Kieny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">214</biblScope>
			<biblScope unit="page" from="46" to="51" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Postacne scarring: a qualitative global scarring grading system</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Baron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatol Surg</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1458" to="1466" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Postacne scarring--a quantitative global scarring grading system</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Baron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cosmet Dermatol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="48" to="52" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">The patient and observer scar assessment scale: a reliable and feasible tool for scar evaluation</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Draaijers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Tempelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Botman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Tuinebreijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Middelkoop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Kreis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Plast Reconstr Surg</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="6" to="7" />
			<date type="published" when="1960">2004. 1960</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">New evidence-based facial acne scar evaluation tool (FASET) to assess atrophic scars</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Layton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Rueda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Petit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page">B9</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Acne is prevalent but use of its treatments is infrequent among adolescents from the general population</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nijsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rombouts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="163" to="168" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Smithard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Glazebrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="274" to="279" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">The prevalence of acne in the north of Portugal</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Amado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Matos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Abreu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Loureiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Verde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1287" to="1295" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">The prevalence of common skin conditions in Australian school students: 3. acne vulgaris</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kilkenny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Merlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Plunkett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="840" to="845" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">The prevalence and risk factors of adolescent acne among schoolchildren in Lithuania: a cross-sectional study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Karciauskiene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Valiukeviciene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="733" to="740" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Prevalence of facial acne in adults</title>
		<author>
			<persName><forename type="first">V</forename><surname>Goulden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Stables</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="577" to="580" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">A global perspective on the epidemiology of acne</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bhate</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Epidemiology of acne vulgaris</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bhate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="474" to="485" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Acne in infancy and acne genetics</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Herane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ando</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">206</biblScope>
			<biblScope unit="page" from="24" to="28" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Association of HSD17B3 and HSD3B1 polymorphisms with acne vulgaris in Southwestern Han Chinese</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">227</biblScope>
			<biblScope unit="page" from="202" to="208" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Navarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Simpson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Carlavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reiniche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">4020</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Acne vulgaris: a disease of Western civilization</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cordain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lindeberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hurtado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Eaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brand-Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="1584" to="1590" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">High school dietary dairy intake and teenage acne</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Adebamowo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spiegelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Danby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Frazier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Willett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Holmes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="207" to="214" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Mann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Braue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Makelainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Varigos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="107" to="115" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo</title>
		<author>
			<persName><forename type="first">D</forename><surname>Verthelyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Klinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="384" to="390" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kistowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Proust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feldmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cozzio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuendig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="110" to="118" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Protease-activated receptor-2 mediates the expression of inflammatory cytokines, antimicrobial peptides, and matrix metalloproteinases in keratinocytes in response to Propionibacterium acnes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Jeon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Jeong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol Res</title>
		<imprint>
			<biblScope unit="volume">302</biblScope>
			<biblScope unit="page" from="745" to="756" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">What is the role of antimicrobial peptides (AMP) in acne vulgaris?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Harder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tsuruta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Murakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kurokawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="386" to="391" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Different strains of Propionibacterium acnes modulate differently the cutaneous innate immunity</title>
		<author>
			<persName><forename type="first">F</forename><surname>Jasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nagy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Knol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zuliani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khammari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="587" to="592" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Propionibacterium acnes strain populations in the human skin microbiome associated with acne</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fitz-Gibbon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tomida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Chiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="2152" to="2160" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Understanding innate immunity and inflammation in acne: implications for management</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Gollnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thiboutot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bettoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Torres</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="3" to="11" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">From new findings in acne pathogenesis to new approaches in treatment</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Gollnick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Lomholt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kilian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e12277</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Propionibacterium acnes Induces IL-1beta secretion via the NLRP3 inflammasome in human monocytes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pirouz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Krutzik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Garban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="381" to="388" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Insulin and insulin-like growth factor-1 can modulate the phosphoinositide-3-kinase/Akt/FoxO1 pathway in SZ95 sebocytes in vitro</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Mirdamadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wiede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Goihl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Papakonstantinou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hartig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Endocrinol</title>
		<imprint>
			<biblScope unit="volume">415</biblScope>
			<biblScope unit="page" from="32" to="44" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges</title>
		<author>
			<persName><forename type="first">D</forename><surname>Pathirana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ormerod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Reytan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saiag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1458" to="1467" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">European S3-guidelines on the systemic treatment of psoriasis vulgaris</title>
		<author>
			<persName><forename type="first">D</forename><surname>Pathirana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ormerod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saiag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Spuls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nast</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Suppl 2; 1-70</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">European evidence-based (S3) guidelines for the treatment of acne</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bettoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Degitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Erdmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl 1; 1-29</note>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Methods report on the development of the European S3 guidelines for the treatment of acne</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosumeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sammain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sporbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rzany</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="e1" to="41" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Vist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Falck-Ytter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alonso-Coello</forename></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page" from="924" to="926" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin</title>
		<author>
			<persName><forename type="first">A</forename><surname>Katsambas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Graupe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stratigos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol Suppl (Stockh)</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="35" to="39" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<monogr>
		<title level="m" type="main">Which anti-acne treatments do patients prefer? Systematic review</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dressler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosumeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nast</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>under review</note>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents</title>
		<author>
			<persName><forename type="first">A</forename><surname>Thielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Helmdach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Röpke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="19" to="27" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%</title>
		<author>
			<persName><forename type="first">A</forename><surname>Thielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="747" to="753" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Almekinder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Drugs Dermatol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="131" to="136" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Treatment of acne with topical antibiotics: lessons from clinical studies</title>
		<author>
			<persName><forename type="first">T</forename><surname>Simonart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dramaix</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="395" to="403" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Combined oral contraceptive pills for treatment of acne</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Arowojolu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Gallo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Grimes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">D004425</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Safety of doxycycline and minocycline: a systematic review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Leyden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1329" to="1342" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Peck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Olsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Butkus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pandya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arnaud-Battandier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Gross</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="735" to="745" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Minocycline in acne vulgaris: benefits and risks</title>
		<author>
			<persName><forename type="first">F</forename><surname>Ochsendorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Dermatol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="327" to="341" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Phototoxic eruptions due to doxycycline--a dose-related phenomenon</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Layton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="425" to="427" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Murphy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="213" to="214" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bjellerup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ljunggren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="356" to="360" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<monogr>
		<title level="m" type="main">European Directive for systemic isotretinoin prescription</title>
		<imprint>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>EMEA -Committee for Proprietary Medicinal Products (CPMP)</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Isotretinoin: state of the art treatment for acne vulgaris</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ganceviciene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Zouboulis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dtsch Dermatol Ges</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S47" to="59" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Guidelines for optimal use of isotretinoin in acne</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Layton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="S2" to="7" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Guidelines of care for acne vulgaris management</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Strauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Krowchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Leyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Lucky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Shalita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Siegfried</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="651" to="663" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Roaccutane treatment guidelines: results of an international survey</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Van De Kerkhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Caputo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cavicchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">L</forename><surname>Fyrand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="351" to="357" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Optimal management of acne to prevent scarring and psychological sequelae</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Layton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Dermatol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="135" to="141" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Rubinow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Peck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Squillace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Gantt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="25" to="32" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Layton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hpm</forename><surname>Gollnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Zouboulis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="773" to="776" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Acute acne flare following isotretinoin administration: potential protective role of low starting dose</title>
		<author>
			<persName><forename type="first">A</forename><surname>Borghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Minghetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Virgili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bettoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">218</biblScope>
			<biblScope unit="page" from="178" to="180" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Low-dose isotretinoin in acne vulgaris: a critical review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sardana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Garg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="698" to="700" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Effectiveness of conventional, lowdose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Seo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="1369" to="1375" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rademaker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Australas J Dermatol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="157" to="162" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Cyrulnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Viola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Gewirtzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1123" to="1130" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Blasiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Stamey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Burkhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lugo-Somolinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Morrell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Dermatol</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="1392" to="1398" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Should isotretinoin be stopped prior to surgery? A critically appraised topic</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Wootton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Cartwright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Manning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="239" to="244" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Marqueling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Zane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Cutan Med Surg</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="210" to="220" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Retinoic acid and affective disorders: the evidence for an association</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Bremner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Shearer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Mccaffery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Psychiatry</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="37" to="50" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Changing patterns of plasmidmediated drug resistance during tetracycline therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Moller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Bak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stenderup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zachariae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Afzelius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="388" to="391" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Evolution of antibiotic resistance at non-lethal drug concentrations</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Resist Updat</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="162" to="172" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Selection of Resistant Bacteria at Very Low Antibiotic Concentrations</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gullberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">G</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ilback</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sandegren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Plos Pathogens</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Snelling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Leyden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<editor>U.S.A., Japan and Australia</editor>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="339" to="346" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Antibiotic-resistant acne: lessons from Europe</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Snelling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Carnegie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Coates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bettoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="467" to="478" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Topical antibiotic therapy: current status and future prospects</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cove</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs Under Experimental &amp; Clinical Research</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="423" to="433" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Escmid Study Group on Antimicrobial Resistance in Anaerobic Bacteria. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Oprica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Nord</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Microbiology &amp; Infection</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="204" to="213" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Nord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Oprica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anaerobe</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="207" to="210" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Propionibacterium acnes (P. acnes) resistance and antibiotic use in patients attending Australian general practice</title>
		<author>
			<persName><forename type="first">H</forename><surname>Toyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Webber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Collignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kljakovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Australas J Dermatol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="106" to="111" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Bacterial resistance in acne</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eady</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="page" from="59" to="66" />
			<date type="published" when="0196">1998. 196</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle</title>
		<author>
			<persName><forename type="first">O</forename><surname>Mills</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thornsberry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Cardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Smiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Leyden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="260" to="265" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Effect of antibiotics on the oropharyngeal flora in patients with acne</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Roling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Leyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Margolis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="467" to="471" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Evaluation of nasal and oropharyngeal flora in patients with acne vulgaris according to treatment options</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ozuguz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Callioglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Tulaci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Kacar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Balta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Asik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1404" to="1408" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="51" to="57" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris</title>
		<author>
			<persName><forename type="first">C</forename><surname>Oprica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Emtestam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hagstromer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Nord</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="246" to="254" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Efficacy of tetracyclines in the treatment of acne vulgaris: a review</title>
		<author>
			<persName><forename type="first">T</forename><surname>Simonart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dramaix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Maertelaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="208" to="216" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Clonality and anatomic distribution on the skin of antibiotic resistant and sensitive Propionibacterium acnes</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Lomholt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kilian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="534" to="538" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ozolins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Avery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Po</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="2188" to="2195" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Harkaway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Mcginley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Foglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fried</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Shalita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="586" to="590" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">The development of antibiotic resistance in Propionibacterium acnes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Leyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Levy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cutis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="21" to="24" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bojar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="107" to="113" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bojar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Levy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1117" to="1133" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Almekinder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Drugs Dermatol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="131" to="136" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Transdermal absorption of clindamycin and tretinoin from topically applied anti-acne formulations in man</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Van Hoogdalem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Baven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Spiegel-Melsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Terpstra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biopharmaceutics &amp; drug disposition</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="563" to="569" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">Potential hazards of clindamycin in acne therapy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Basler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="383" to="385" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">In vivo antibacterial effects of tretinoin-clindamycin and clindamycin alone on Propionibacterium acnes with varying clindamycin minimum inhibitory</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Leyden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Drugs Dermatol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1434" to="1438" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bojar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Holland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="329" to="336" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">Zindaclin Clinical Study G. An observerblind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bojar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kanis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>West</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatolog Treat</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="213" to="218" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris</title>
		<author>
			<persName><forename type="first">A</forename><surname>Langner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sheehan-Dare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Layton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="311" to="319" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne</title>
		<author>
			<persName><forename type="first">R</forename><surname>Skidmore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kovach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bradshaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leyden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="459" to="464" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b157">
	<monogr>
		<title level="m" type="main">Microbiological changes associated with four different periodontal therapies for the treatment of chronic periodontitis. Oral microbiology and immunology</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Haffajee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Socransky</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="148" to="157" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Acne and Related Disorders</title>
		<author>
			<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Elzouki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Harfi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nazer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Stapleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Whitley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Textbook of Clinical Pediatrics</title>
				<meeting><address><addrLine>Berlin</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2012">2012</date>
			<biblScope unit="page" from="1447" to="1466" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b159">
	<monogr>
		<title level="m" type="main">How much do we know about maintaining treatment response after successful anti-acne therapy? Systematic review on the efficacy and safety of anti-acne maintenance therapy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dressler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosumeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nast</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>under review</note>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%</title>
		<author>
			<persName><forename type="first">A</forename><surname>Thielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="747" to="753" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main">Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Thiboutot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Shalita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Yamauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kerrouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arsonnaud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="597" to="602" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline</title>
		<author>
			<persName><forename type="first">M</forename><surname>Alirezai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Coutts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Roseeuw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Hachem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kerrouche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Dermatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="45" to="51" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatolog Treat</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="372" to="378" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main">A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Poulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bucko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jarratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kempers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="1376" to="1382" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main">A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne</title>
		<author>
			<persName><forename type="first">A</forename><surname>Thielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wiede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kropf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Papakonstantinou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gollnick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="789" to="796" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main">Double-blinded, vehicle-controlled proof of concept study to investigate the recurrence of inflammatory and noninflammatory acne lesions using tretinoin gel (microsphere) 0.04% in male patients after oral isotretinoin use</title>
		<author>
			<persName><forename type="first">R</forename><surname>Vender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vender</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatol Res Pract</title>
		<imprint>
			<biblScope unit="page">736532</biblScope>
			<date type="published" when="2012">2012. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
